Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Apr 8.
Published in final edited form as: Cancer Cell. 2024 Mar 7;42(4):583–604.e11. doi: 10.1016/j.ccell.2024.02.010

ARID1A Orchestrates SWI/SNF-mediated Sequential Binding of Transcription Factors with ARID1A Loss Driving Pre-memory B-cell Fate and Lymphomagenesis

Darko Barisic 1,*, Christopher R Chin 1,2,3,*, Cem Meydan 2,3,*, Matt Teater 1, Ioanna Tsialta 1, Coraline Mlynarczyk 1, Amy Chadburn 4, Xuehai Wang 11, Margot Sarkozy 1, Min Xia 1, Sandra E Carson 5, Santo Raggiri 1, Sonia Debek 1,14, Benedikt Pelzer 1, Ceyda Durmaz 6, Qing Deng 8, Priya Lakra 8, Martin Rivas 1,13, Christian Steidl 9,12, David W Scott 9,10, Andrew P Weng 11,12, Christopher E Mason 2,3, Michael R Green 7,8, Ari Melnick 1,15
PMCID: PMC11407687  NIHMSID: NIHMS1970556  PMID: 38458187

Summary:

ARID1A, a subunit of the canonical BAF nucleosome remodeling complex, is commonly mutated in lymphomas. We show that ARID1A orchestrates B cell fate during the germinal center (GC) response, facilitating cooperative and sequential binding of PU.1 and NF-kB at crucial genes for cytokine and CD40 signaling. The absence of ARID1A tilts GC cell-fate towards immature IgM+CD80-PD-L2- memory B cells, known for their potential to re-enter new GCs. When combined with BCL2 oncogene, ARID1A haploinsufficiency hastens the progression of aggressive follicular lymphomas (FL) in mice. Patients with FL with ARID1A-inactivating mutations preferentially display an immature memory B cell-like state with increased transformation risk to aggressive disease. These observations offer mechanistic understanding into the emergence of both indolent and aggressive ARID1A-mutant lymphomas through the formation of immature memory-like clonal precursors. Lastly, we demonstrate that ARID1A mutation induces synthetic lethality to SMARCA2/4 inhibition, paving the way for potential precision therapy for high-risk patients.

Keywords: Pioneer Transcription Factors, Chromatin, Plasticity, Clonal Precursor Cells, BAF Complex, Chromatin Remodeling, Epigenetics, Humoral Immunity, Lymphoma, Precision Therapy

eTOC Blurb:

Barisic et al. show a chromatin remodeling mechanism by which the BAF complex enables stepwise binding of PU.1 and NF-kB factors, thus restricting the memory B cell program and transformation to an aggressive form of lymphoma.

Graphical Abstract

graphic file with name nihms-1970556-f0009.jpg

Introduction:

The BAF chromatin remodeling complex (BRG1/BRM-associated factors) of the SWI/SNF (Switch/Sucrose Non-Fermentable) family of proteins governs the accessibility of DNA by sliding, ejecting, or reconfiguring nucleosomes, thereby regulating gene expression1–7. The biological function of BAF complexes and their role in facilitating DNA binding of transcription factors (TFs) is highly cell-context specific8,9. The versatility of their function is derived from their composition, encompassing more than a dozen subunits with several isoforms, each selectively integrated to create distinct complexes10–14. This variation equips BAF complexes with an extraordinary ability to adapt and execute a wide range of biological functions15. However, even minor alterations in a given subunit can significantly impact the complex function, and when dysregulated contribute to diseases, including cancer8,16.

In mammalian cells, there are three distinct BAF complexes including canonical BAF (cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (ncBAF). Recent studies indicate that nearly 20% of all human malignancies contain mutations in one or more components of different BAF complexes16. The cBAF subunit ARID1A is critical for its chromatin targeting and is the most frequently mutated subunit across cancers8. These mutations often result in loss of function17–22. Despite their established role in the emergence and progression of cancers, the precise mechanisms underlying the transformative potential of ARID1A mutations remain elusive23.

ARID1A mutations are especially prevalent in follicular lymphoma (FL) and diffuse large B cell lymphomas (DLBCL)24–26. DLBCLs are a group of diverse and aggressive tumors that can be classified into several genetically-defined subtypes, each having a unique mutation pattern27–29. The most common subtype of DLBCL (EZB/C3) is characterized by somatic mutations in epigenetic and chromatin regulatory proteins, such as KMTD2, CREBBP, and EZH230, and shows the highest enrichment for ARID1A mutations28. In contrast, FLs are typically indolent tumors, although certain patients are at risk for transformation into a more aggressive and often refractory DLBCL-like lymphoma. Our current understanding of FL does not allow accurate predictions of which patients will undergo transformation, and the underlying mechanisms of transformation remain unclear.

FLs and DLBCLs arise from mature B cells engaged in the humoral immune response30, during which they establish temporary structures known as germinal centers (GCs). GC B cells experience extensive and rapid shifts in their chromatin and transcriptional programs as they cycle back and forth between proliferative bursting and T cell-directed selection and subsequent cell-fate decisions30. Proliferative bursting coincides with immunoglobulin gene somatic hypermutation, which leads to generation of B cells encoding high affinity antibodies31. Regrettably, this process inadvertently introduces numerous off-target mutations, which contribute to lymphomagenesis30. These rapid phenotypic changes are dictated by dynamic chromatin changes, likely overseen by specific TFs31. Our knowledge regarding the interplay between TFs and chromatin remodelers in directing successive phases of this chromatin reorganization and their contribution to lymphomagenesis remain limited.

Interestingly, chromatin accessibility profiling of different GC B cell populations revealed significant changes in chromatin states32. These findings suggest a crucial role of BAF complexes in shaping GC phenotypes and cell fates. Collectively, these considerations led us to explore the molecular, chromatin and biological impact of ARID1A mutations, and their role in the onset and progression of lymphomas.

Results:

Arid1a deletion disrupts germinal center dynamics and progression

Analyzing publicly available datasets we found BAF complex genes to be frequently mutated in FLs and DLBCLs, with ARID1A mutations occurring in 15% of FLs and 12% of GCB-DLBCLs (Figure S1A). These mutations predominantly yielded a truncated protein lacking a critical BAF-interaction C-terminal domain, indicative of loss-of-function (Figure 1A). FL and DLBCL originate from GC B cells, and we therefore investigated the effect of Arid1a loss in GC formation (Figure S1B). Arid1a-floxed mice were crossed with Cg1-Cre mice to yield conditional (cKO) Arid1a deletion in GC B cells. To investigate the GC response, we immunized Arid1a+/+;Cg1Cre/+, Arid1a+/;Cg1Cre/+ and Arid1a−/−;Cg1Cre/+ animals with sheep red blood cells (SRBCs; Figure S1C-E). We observed a gene dosage-dependent decrease of GC B cells (Figure 1B and S1C), a surprising result considering mutations in many DLBCL-tumor suppressor genes result in GC expansion. GC B cell populations include centroblasts (CBs), which experience proliferative bursting and somatic hypermutation, as well as post-replicative centrocytes (CCs)31. We observed increased proportions of CB (vs. CC), in an Arid1a dose-dependent manner (Figure S1C). We hypothesized that the GC reduction could be attributed to an accelerated GC exit and differentiation. To investigate this, we performed a detailed molecular characterization of these cells.

Figure 1. ARID1A facilitates chromatin accessibility for PU.1 and NF-kB during B-cell transitions in germinal centers.

Figure 1.

A. Mutational burden of ARID1A in DLBCL patients 80.

B. Assay schematic and quantification of splenic B cells for three independent experiments (each n>3). Horizontal lines indicate mean, t-test was used.

C. Heatmap showing log2FC in Arid1a+/− or Arid1a−/− vs. Arid1a+/+ in CB/CC. ATAC-seq peaks shown are union of all samples. Peaks were ordered by log2FC, with individual peaks summarized as a histogram. |log2FC|>1.2 colored as orange or red for Arid1a+/− and Arid1a−/− respectively.

D. Peak summary of (A) showing pseudo-median reads as FPKM in CB/CC.

E. Box and whisker plot showing the median, first and third quartiles, and the minimum and maximum log2FC of promoter (+/−2kb TSS) and non-promoter peaks in Arid1a+/− or Arid1a−/− mice compared to Arid1a+/+ in CB/CC. Wilcoxon rank sum performed to compare promoter peaks to non-promoter peaks; all comparisons p-values<1.0e-300.

F. Cell line generation schematic.

G. Same as (C) for human Q474*/WT or sh-KD cells vs. WT/WT.

H. Peak summary of (E) showing pseudo-median reads normalized by FPKM in Q474*/WT vs. WT/WT.

I. Same as (E) for Q474*/WT vs. WT/WT.

J. 3U or 5U MNase-digested nuclei DNA electrophoresis in Q474*/WT or WT/WT.

K. Normalized MNase signal centered on ATAC peak summit.

L. Genome browser track showing Q474*/WT and WT/WT MNase tracks alongside ATAC peaks.

M. Q474*/WT vs. WT/WT nucleosome positions with significant fuzziness score

(p.adj<0.05, calculated by DANPOS). Grey box indicates nucleosomes highly positioned in WT/WT that gain fuzziness in Q474*/WT.

N. Ranked loci based on Q474*/WT vs. WT/WT fuzziness log2FC.

O. CUT&RUN for H3K27me3 in RIVA cells. Heatmaps show +/−10kb of ATAC peak summits with significant loss upon Arid1a deletion (Wald q<0.05, |log2FC|>0). Summary plots show median reads normalized by FPKM.

P. Same as (O) for H3.3 CUT&RUN.

See also Figure S1

ARID1A loss leads to widespread chromatin repression and decrease in active nucleosome turnover

B cells feature shifting patterns of chromatin accessibility during the GC reaction32. To determine whether this is controlled by ARID1A we performed the assay for transposase-accessible chromatin with sequencing (ATAC-seq)33 on sorted CBs and CCs. Ranking ATAC-seq peaks showed extensive, gene dose-dependent loss of chromatin accessibility in Arid1a+/− and Arid1a−/− cells (Figure 1A, 1B, S1F). Importantly, Arid1a+/− profiles yielded partial reduction of accessibility at the same regions affected (more severely) in Arid1a−/− GCs, indicating loss of function in Arid1a+/− cells. Previous work showed that cBAF complex preferentially regulates distal regions (enhancers), while PBAF tends to function at promoters34. Accordingly, distal regions were more affected than promoters in Arid1a deficient GCs (Figure 1E).

To determine potential relevance for disease we profiled human DLBCL cells (RIVA/RI-1) derived from a patient with a nonsense heterozygous Q474* ARID1A mutation. CRISPR knock-in was used to repair the ARID1A mutation, and we selected repaired (WT/WT) as well as control clones that underwent selection but did not repair the allele (Q474*/WT; Figure S1G). Notably, ARID1A protein expression doubled upon CRISPR-repair in WT/WT cells (Figure S1G). An inducible short hairpin (sh) knockdown construct was integrated into Q474*/WT cells (sh-KD) to further reduce ARID1A levels (Figure 1F). This system exhibited high inducibility and negligible cassette expression pre-induction (Figure S1H and S1I). ATAC-seq of these Q474*/WT, WT/WT and shKD clones showed ARID1A gene dose-dependent decrease in chromatin accessibility (Figure 1G and 1H), with higher degree of chromatin compaction at non-promoter regions in Q474*/WT DLBCL cells (Figure 1I).

We next investigated the impact of ARID1A deficiency on nucleosome occupancy and positioning. Nuclei from Q474*/WT DLBCL cells exhibited increased resistance to Micrococcal nuclease digestion (MNase; 3U of enzyme), indicating global increase in chromatin compaction (Figure 1J). Examining our ATAC-seq data we observed increased nucleosome occupancy over the summit of ATAC peaks, indicating invasion of nucleosomes at these sites in ARID1A mutant cells (Figure 1K and 1L), which was still evident at higher nuclease concentration (5U) (Figure 1K).

To ascertain whether the increase in nucleosome occupancy was accompanied by a decrease in well-defined nucleosome positions, we assessed nucleosome fuzziness on a genome-wide scale35. Nucleosome fuzziness refers to variation in nucleosome positions (within each nucleosome peak) from the most preferred position and was measured utilizing the standard deviation of read positions in each peak. In Q474*/WT cells, we observed an increase in nucleosome fuzziness score specifically at nucleosomes that were highly positioned (low fuzziness score) in WT/WT (Figure 1M). There was also a marked increase of nucleosomes with significantly increased fuzziness (n=1,093,285 for Q474*/WT and WT/WT n=678,040; Figure 1N), indicating loss of well-defined nucleosomes in ARID1A mutant cells.

The BAF complex can displace PRC2 complexes from chromatin with corresponding reduction in H3K27me336,37. Profiling H3K27me3 distribution we observed increased enrichment at loci with decreased accessibility In Q474*/WT cells (Figure 1O), suggesting chromatin repression. Given that the H3.3 histone variant is a hallmark of active nucleosome turnover38–40 we examined whether ARID1A deletion prevents incorporation of nucleosomes into chromatin and observed a marked decrease in nucleosome turnover at locations with impaired accessibility In Q474*/WT cells (Figure 1P). These results show the importance of ARID1A in maintaining chromatin accessibility and nucleosome patterns in B cells, with its loss leading to chromatin closing, disruptions in nucleosome positioning, and loss of nucleosome turnover.

ARID1A enables chromatin opening for PU.1 and NF-kB during germinal center B-cell transitions

Arid1a loss of function caused skewing of the GC reaction towards CBs and away from CCs (Figure S1C). This led us to test whether a primary role of ARID1A is to enable the CB to CC transition through its effect on chromatin accessibility. Unsupervised hierarchical clustering and Principal Component Analysis (PCA) of CB and CC ATAC-seq profiles revealed that their primary difference is driven by genotypes, followed by cell types (Figure 2A and 2B), suggesting that Arid1a loss induces even more substantial chromatin reorganization than the CB to CC transition. RNA-seq on the same cells showed significant correlation between changes in chromatin accessibility and expression of nearby genes, linking the effect of ARID1A on chromatin to gene expression (Figure 2C and Table S1).

Figure 2. ARID1A facilitates chromatin accessibility for PU.1 and NF-kB during B-cell transitions in mouse germinal centers.

Figure 2.

A. Mouse Arid1a+/+, Arid1a+/− and Arid1a−/− ATAC-seq Manhattan Distance of CB or CC cells for peaks with SD>0.5.

B. Same as (A) for PCA analysis.

C. Box and whisker plot showing the median, first and third quartiles, and the minimum and maximum ATAC-seq log2FC of peaks within 10kb of a gene body, categorized by differential gene expression (Wald q<0.05, |log2FC|>0) in Arid1a+/− vs. Arid1a+/+ CB (top) or CC (bottom). P-value calculated using ANOVA.

D. Regulatory potential showing top TFs with increased motif accessibility in Arid1a+/+ CC vs. CB ATAC-seq, colored by multivariate adjusted p-value (p-adj). Estimated coefficient shown as bar plots +/− 95% confidence interval (CI).

E. Regulatory potential showing top TFs that have decreased motif accessibility in Arid1a+/−vs. Arid1a+/+ (multivariate with cell type regressed out), colored by multivariate p-adj. Estimated coefficient shown as bar plots +/− 95% CI.

F. Supervised k-means clustering of differentially accessible peaks between Arid1a+/+, Arid1a+/− and Arid1a−/− CC, normalized to WT/WT CB.

G. Peaks from categories shown in (F) linked to the nearest gene within 10kb and corresponding PAGE analysis of GC exit signaling pathways.

H. Fisher’s exact test for presence of the indicated TF motif enrichment in each cluster from (F).

I. TOBIAS footprint binding score analysis for PU.1 (left) and NF-kB2 (right). P-values generated by TOBIAS-BINDetect function.

J. GSEA Normalized Enrichment Score (NES) of PU.1 gene signatures in Arid1a+/+ vs. Arid1a+/− (left) or Arid1a−/− (right) mouse CC cells. FDR calculated through GSEA permutation test.

See also Figures S1 and S2 and Table S1.

Changes in chromatin accessibility are thought to depend on recruitment of BAF complexes by specific TFs. We first aimed to identify TFs that open chromatin during the normal CB to CC transition. Using a TF motif accessibility regulatory potential model controlling for genomic covariates32, we discovered strong enrichment for motifs of known BAF-interacting TFs8, notably PU.1 and NF-kB (Figure 2D). To determine whether Arid1a deficiency impairs accessibility at these sites, we examined accessibility regulatory potential in Arid1a+/− vs. Arid1a+/+ GC B cells, finding that PU.1 was the most perturbed, followed by NF-kB factors and others (Figure 2E). Importantly, there was no discernible change in Spi1 (PU.1) gene expression when comparing Arid1a+/− to Arid1a+/+ in either CBs or CCs (Figure S2A). This was also true for NF-kB factors (Figure S2B). Hence, the loss of accessibility at PU.1 and NF-kB binding sites is likely due to decrease in their chromatin binding capacity, rather than expression levels of these TFs.

We further classified differential accessibility upon Arid1a deletion based on peak opening or closing in the WT CB to CC transition (Figure 2F and Table S1). The highest proportion of peaks that closed upon Arid1a loss (cluster 4) were those expected to open in normal CCs. Many genes in this category play critical roles in CC exit from the GC reaction41, including the CD40, NF-kB, STAT3, IL2, IL4, IL6 and Notch pathways, as well as IRF4 and other plasma cell (PC) differentiation signatures (Figure 2G and Table S1). We performed motif analysis to identify enriched TFs within the four clusters. Notably, PU.1 (and the closely related SPIB) motifs were enriched across all Arid1a+/−closing peaks (Figure 2H and Table S1). In contrast, NF-kB motifs exhibited enrichment specifically in peaks that fail to open in Arid1a+/− CCs (cluster 4). We then used the TOBIAS footprinting analysis42 to directly link chromatin accessibility loss to changes in PU.1 and NF-kB DNA binding and observed significant reduction in binding for both factors (Figure 2I). Accordingly, there was significant enrichment for the B cell PU.1 knockout gene expression signature43 in our Arid1a+/− GC B cells (Figure 2J).

PU.1 and NF-kB require ARID1A for binding and activation of germinal center exit genes in lymphoma cells

To extend our findings to human lymphoma cells, we analyzed chromatin features of our isogenic RIVA/RI-1 cells. Unsupervised hierarchical clustering of ATAC-seq profiles showed clear separation based on genotypes (Figure 3A). RNA-seq analysis corroborated the correlation between differential gene expression and chromatin accessibility (Figure 3B and Table S2). Closing peaks were enriched for CD40, NF-kB, IRF4, interleukin/STAT induced genes, among others, similar to mouse GC B cells (Figure 3C and Table S2). We further observed that PU.1 and NF-kB motifs were the most perturbed based on regulatory potential, which occurred in a dose-dependent manner in Q474*/WT and sh-KD cells (Figure 3D). TOBIAS analysis showed reduction in PU.1 and NF-kB footprinting score suggesting impaired DNA binding (Figure 3E).

Figure 3. ARID1A facilitates chromatin accessibility for PU.1 and NF-kB during B-cell transitions in human lymphoma cells.

Figure 3.

A. Manhattan distance in DLBCL cell line (RIVA/RI-1) of ATAC-seq peaks with a SD>0.5.

B. Box and whisker plot showing the median, first and third quartiles, and the minimum and maximum ATAC-seq log2FC of peaks within 10kb to gene body grouped by differential gene expression (Wald q<0.01, |log2FC|>0.58) between WT/WT and Q474*/WT direction

C. Differentially (Wald q<0.01, |log2FC|>0.58) opening or closing peaks linked to the nearest gene within 10kb and corresponding PAGE analysis of GC exit signaling pathways in (hypergeometric q<0.05

D. Regulatory potential of top TF motifs closing in Q474*/WT vs. WT/WT (top) or KD vs. WT/WT (bottom), colored by multivariate p-adj. Estimated coefficient shown as bar plots +/− 95% CI.

E. Bar plot representing TOBIAS footprint binding score of PU.1 (top) or NF-kB2 (bottom) in Q474*/WT, WT/WT and KD cells. P-values generated by TOBIAS-BINDetect function.

F. Overlap of ChIP-seq (PBRM1 and SMARCA4) and CUT&RUN (ARID1A and BRD9) peaks in WT/WT RIVA/RI-1 cells.

G. Venn diagram showing the overlap of ARID1A WT/WT CUT&RUN peaks and significantly (Wald q<0.05) opening/closing ATAC peaks in Q474*/WT vs. WT/WT.

H. Heatmaps showing log2FC for ARID1A, PRBM1 or IgG control at differentially (Wald q<0.05) closing ATAC peaks in order of decreasing ARID1A log2FC. Summary plots show mean FPKM of Q474*/WT and WT/WT binding signal.

I. Same as in (H) for PU.1 ChIP-seq motif shown in the order of PU.1 log2FC.

J. PAGE Analysis of genes closest to IgG or PU.1 peaks for GC exit signatures.

K. Genome browser track showing PU.1, ARID1A and H3.3.

L. Unsupervised clustering of peaks based on WT/WT and Q474*/WT ATAC-seq, H3K27Ac and H3K27me3 signal. Delta indicates Q474*/WT vs. WT/WT unless stated otherwise.

M. Summaries of region size and peak number for each peak cluster. Dots in violin plots represent median, lines represent first and third quartiles.

N. Median of RNA expression log2 fold-change for genes closest to respective peaks in each cluster.

O. Log2FC difference between genotypes for the indicated BAF subunit and cluster.

P. Peak cluster annotation percentage for promoter, enhancer or super-enhancer.

Q. Peak cluster percentage containing motifs from SPI1/SPIB, NF-kB or both.

See also Figure S2 and Table S2.

Having confirmed consistency between human DLBCL and mouse GC B cells, we next evaluated whether sites losing accessibility were direct targets of the cBAF complex. For this we profiled genomic binding of ARID1A (cBAF), PBRM1 (PBAF), SMARCA4 (cBAF, PBAF and ncBAF), and BRD9 (ncBAF) in Q474*/WT and WT/WT cells. As expected, the majority of ARID1A peaks were a subset of SMARCA4 peaks, as were PBRM1 and BRD9 peaks (Figure 3F and Table S2), consistent with the known distributions of BAF complexes bound to chromatin12,34. 47.0% of sites with significant reduction in chromatin accessibility in Q474*/WT DLBCL cells were direct ARID1A target genes, in contrast to 14.2% among sites gaining accessibility (Figure 3G). Moreover, we observed reduced ARID1A binding across ATAC peaks closing in Q474*/WT, but no discernible changes in PBRM1, consistent with these effects being cBAF-specific (Figure 3H).

To test whether loss of PU.1 motif accessibility corresponds to loss of PU.1 occupancy, we profiled PU.1 genomic binding in Q474*/WT compared to WT/WT cells. 50% of the PU.1 specific peaks contained canonical PU.1/SpiB motifs (Figure S2C). We observed significant loss of PU.1 binding at sites with impaired accessibility in Q474*/WT cells (Figure 3I and Table S2), indicating that PU.1 requires ARID1A for binding at these sites. Validating whether these binding sites are similar in primary GC B cells we found significant enrichment for PU.1 direct binding sites in human primary GCB cells (Figure 3J). Similar to the Arid1a deficient signature, PU.1 peaks enriched for CD40 response, IRF4, and cytokine/interleukin target gene sets (Figure 3J). Regions with loss of PU.1 also showed decrease of ARID1A and H3.3 (Figure 3K). Finally, loss of accessibility at NF-kB sites resulted in significantly decreased binding of NF-kB TFs (Figure S2D).

To characterize and integrate the functional impact of ARID1A on different chromatin states in an unbiased manner, we generated computational models that cluster genomic regions based on chromatin accessibility, H3K27me3 and H3K27ac patterns, as well as their variability between genotypes. This approach yielded 16 clusters with specific chromatin features (Figures 3L, 3M S2E and Table S2). Clusters showing a reduction in both chromatin accessibility and H3K27ac (C1–3, 8, 11) displayed transcriptional downregulation (Figure 3N) and the most significant ARID1A binding loss (Figure 3L and 3O). To a lesser extent, these regions showed reduced loading of pan-BAF subunits SMARCA4 and SMARCC1, consistent with ARID1A being required to form functional cBAF complexes12 and for correct genomic targeting34 (Figure 3O). Consistent with these effects being cBAF-specific, we observed no reduction in PBAF (PBRM1) loading at these loci. Concurrent with cBAF binding loss, we observed reduction of nucleosome turnover (as measured by H3.3 abundance) and PU.1 loading (Figure 3O). Among annotated DNA elements, clusters with loss of accessibility and cBAF were primarily linked to GC B cell enhancers and super-enhancers (Figure 3P) that contained peaks with either PU.1 and NF-kB motifs or both motifs together (Figure 3Q), suggesting potential cooperativity between these TFs.

Co-dependency of PU.1 and NF-kB on ARID1A marks the regulation of accessibility at GC cell-fate genes.

We aimed to further elucidate the requirement of both NF-kB and PU.1 for activation of GC exit genes. Using our RIVA/RI-1 ATAC-seq, we discovered substantial co-occurrence of chromatin accessibility peaks with both NF-kB and PU.1 DNA motifs (Figure 4A). Remarkably, the most pronounced chromatin closing occurred at peaks containing both PU.1 and NF-kB motifs, vs. peaks containing either factor alone (Figure 4A), suggesting that PU.1 might facilitate binding of NF-kB. A pathway analysis showed that CD40 signaling and B cell NF-kB targets were most significantly enriched among peaks containing both NF-kB and PU.1 DNA motifs, compared with peaks containing either PU.1 or NF-kB motifs alone (Figure 4B). Furthermore, certain pathways traditionally associated with NF-kB signaling (such as AKT1 and IGF1) were solely dependent on NF-kB DNA motifs, with no evident reliance on PU.1. In contrast, cytokine signaling pathways known to be linked to PU.1 function44,45 were specifically enriched for PU.1 but not NF-kB motifs (Figure 4B). Therefore, ARID1A is specifically required for cooperative effects between NF-kB and PU.1 in the activation of a specific subset of GC exit genes.

Figure 4. NF-kB mediated gene-activations requires both ARID1A and PU.1.

Figure 4.

A. Venn diagram showing ATAC-seq peaks across all genotypes with motifs for SPI1, NF-kB, or both (top). GSEA enrichment scores for each category (middle), based on ATAC log2FC ranking of Q474*/WT vs. WT/WT (bottom). GSEA permutation test p-values<0.001.

B. Enrichment of gene signatures based on hypergeometric analysis of genes within 10kb of peaks grouped by motif presence. Bar plots show -log10 Hypergeometric P-values.

C. NF-kB luciferase reporter assay in Raji cells WT/WT and Q474*/WT. Bar chart of mean with error bars representing SD and replicates as dots shown. t-test was used.

D. Same as (C) for NF-kB luciferase reporter assay in Raji cells with and without CRISPR targeted to the PU.1 motif in the NF-kB reporter, 48h post-CRISPR.

E. Heatmap of ATAC-seq peaks binned by distance of TF motif (SPI1 and NF-kB) to peak summit, colored by log2FC of ATAC signal. Includes only peaks that contain both motifs.

F. Violin plot showing median and interquartile range of log2FC of peaks in (F) divided into two bins: motif within 150bp of the ATAC summit, or motif situated more than 150bp away from the summit. Wilcoxon rank sum was performed between different bins.

G. Proposed model of PU.1, cBAF and NF-kB chromatin remodeling.

See also Figure S3.

To assess ARID1A requirement for PU.1 and NF-kB-driven gene expression, we stably integrated an NF-kB-response element reporter in Raji cells46. We used CRISPR to knock-in the Q474*/WT mutation into the ARID1A locus (Figure S3A). Notably, Q474*/WT Raji cells manifested significant reduction in luciferase expression compared to WT/WT cells (Figure 4C). The reporter also contained PU.1 motifs in proximity to the NF-kB response element. To determine the extent to which PU.1 binding was necessary for NF-kB activity we used CRISPR to disrupt the strongest PU.1 motif, which was separated from the NF-kB elements by half of nucleosomal length (75bp) (Figure S3B). CRISPR deletion of the PU.1 motif induced a significant >3-fold reduction in luciferase expression (Figure 4D). Given that ARID1A deficiency impaired opening of NF-kB target genes in CC in vivo (Figure 4G) we tested whether signaling induced activation of the NF-KB reporter was similarly impaired. Indeed, PMA/IO (phorbol 12-myristate 13-acetate/ionomycin) induction of NF-kB reporter activity was strongly and significantly impaired in Raji cells with PU.1-motif disruption (>4-fold decrease; Figure 4D). These findings suggest that PU.1 is required to open NF-kB elements through ARID1A nucleosome remodeling activity.

If this mode of co-regulation is mediated by nucleosome remodeling, it would require close proximity between PU.1 and NF-kB motifs at ARID1A dependent loci. To investigate this, we examined chromatin accessibility peaks containing both PU.1 and NF-kB motifs (Figure 4E). When peaks were arranged according to the distance separating the two motifs, we noted the most substantial and significant decrease in accessibility at peaks where motifs were within 75 base pairs of one another, compared to peaks with greater distance between motifs (Figure 4E and 4F). Thus, ARID1A nucleosome remodeling is especially required at closely positioned PU.1 and NF-kB binding sites. Moreover, the fact that NF-kB requires PU.1 binding at these sites suggests that PU.1-mediated chromatin opening through ARID1A might precede and facilitate the subsequent binding of NF-kB (Figure 4G).

ARID1A enables sequential and cooperative function of PU.1 and NF-kB with ARID1A deficiency driving cell-fate decisions toward a pre-memory B-cell state

To determine the functional impact of ARID1A loss in CC transcriptional programming, we performed combined single-cell RNA- and ATAC-seq (Multiome) on GC B cells from Arid1a+/−, Arid1a−/− or Arid1a+/+ mice. We annotated GC B cell clusters as CB, transitioning from CB to CC, CC, recycling (CC to CB), pre-memory, and pre-plasma cells by transferring labels from published datasets47 (Figure 5A and Figure S4A). We observed expansion of pre-memory B cells programmed to exit as memory B (MB) cells, and reciprocal decrease in pre-plasma cells (programmed to exit as plasmablasts) in Arid1a+/− and Arid1a−/− animals (Figure 5B). We confirmed that pre-memory cluster cells expressed MB-associated genes (Cd38 and Klf2) and the pre-memory signature (Figure 5C).

Figure 5. Loss of ARID1A alters cell-fate towards a Pre-Memory state by disrupting sequential PU.1 then NF-kB function on chromatin.

Figure 5.

A. UMAP of Multiome RNA- and ATAC-seq with cell types labels from a reference dataset based on RNA expression.

B. UMAP of cells split and colored by genotype.

C. UMAP projection of indicated gene expression (Klf2, Cd38).

D. Cell type density along pseudotime based on RNA expression for each cell type in the lineage, anchored at CB.

E. Density difference between Arid1a+/− and Arid1a+/+ along pseudotime. Wilcoxon Rank Sum p-value of Arid1a+/− vs. Arid1a+/+ pseudotime <2.2e-16.

F. Expression of prememory genes (GSE89897) across pseudotime, 99% confidence interval shown in grey.

G. Difference in prememory gene expression across pseudotime between Arid1a+/− and Arid1a+/+. Pseudotime values were broken into 10 deciles and Wilcoxon rank sum was performed between genotypes. Each significant decile is colored red with the minimum p<1.82e-45.

H. Motif accessibility across pseudotime of the indicated TF, 95% confidence interval shown in grey.

I. Motif accessibility difference across pseudotime for specified TF between genotypes (bottom). Significant deciles are red with minimum PU.1 p<3.83e−4, and minimum significant NF-KB p<1.84e−3; grey for non-significant.

J. TPM log2FC RNA-seq expression of MB cell genes for each replicate of RIVA/RI-1 cells Q474*/WT and WT/WT. Genes ranked on average log2FC. CXCR4 is included to highlight similarity between mouse CB expansion phenotype with transcriptional regulation of human DLBCL cells upon ARID1A deletion.

K. RT-PCR relative mRNA abundance of individual memory B cell genes normalized to GAPDH, dots represent mean of three technical replicates, bars represent the mean of a different CRISPR clone, error bars represent SD.

L. TOBIAS motif footprinting score of KLF2 and BCL6 based on ATAC-seq from Q474*/WT, WT/WT and KD cells. P-values generated by TOBIAS BINDetect function.

M. GSVA of Memory B cell signature in Q474*/WT or WT/WT cells.

See also Figure S4.

To further explore how Arid1a loss of function might alter the progression of transcriptional programs during the GC reaction, we used Slingshot48 to generate a pseudo-time trajectory that leads from CB to the pre-MB cell fate (Figure 5D). Plotting cell density for each genotype along the pseudo-time axis, we noted a significant (p<2.2×10−16) shift in distribution favoring pre-memory B cells in Arid1a+/− vs. Arid1a+/+ mice (Figure 5E), which was noted across all GC B cell populations (Figures 5F and 5G). Furthermore, eliminating the pre-memory population from the pseudo-time trajectory analysis and focusing on CB to CC transition allowed us to confirm the skew towards CB in Arid1a−/+ cells, consistent with our phenotype (Figure S4B). These data suggest that Arid1a loss of function favors GC exit towards the MB cell fate at the expense of PCs.

To determine if these population shifts are linked to impaired PU.1 and NF-kB function, we assigned single-cell ATAC-seq profiles to single-cell RNA-seq defined populations using their shared multiome barcodes. We calculated single-cell motif accessibility scores for these TFs along the pseudo-time axis, which revealed significant and sustained loss of PU.1 motif accessibility starting from the early CB stage in Arid1a+/− mice (Figure 5H and 5I). In contrast, significant loss of accessibility at NF-kB motifs developed later in the trajectory as cells began to transition towards the CC state, suggesting a hierarchy between these factors whereby loss of PU.1 binding leads to subsequently impaired NF-kB function.

Examining our human isogenic DLBCL cells we also observed robust and significant upregulation of canonical MB cell genes, such as CD27, CD38, FCRL5, KLF2, and CEACAM21, and master regulators of the MB cell transcriptional program (BACH2 and HHEX, Figure 5J and 5K)49. We noted upregulation of MAP2K5, which induces expression of KLF2, a TF linked to the MB program50,51. Reciprocally, we observed reduced expression of the canonical GC B cell TF BCL6, another MB hallmark41,52,53. This was accompanied by increased KLF2 and reduced BCL6 TOBIAS footprint scores (Figure 5L). Finally, a GSVA analysis showed that correction of Q474*/WT to WT/WT restored GC transcriptional programming, and shifted away from the MB signature (Figure 5M). The fact that the pre-MB cell program is retained by ARID1A mutant DLBCL cells suggests its relevance to malignant transformation.

Arid1a heterozygosity enhances germinal center production of immature memory B cells

We next investigated the biological impact of these transcriptional and multiome findings in vivo. We isolated spleens from mice at 10, 16, and 21 days post-immunization, representing GC peak activity and resolution (Figure S5A). As shown earlier, GC B cells were reduced in abundance in Arid1a+/− mice (data not shown). In contrast, we observed a significant increase in the abundance of MB cell-containing populations (B220+CD138−FAS-CD38+IgD−) throughout the entire time course (Figure S5B-D). This persisted even when measured relative to GC B cells, from which they presumably originate (Figure S5C). Intriguingly, Arid1a+/− mice produced a higher proportion of IgM+ MB cells, representing non class-switched, potentially less mature MB cells (Figure S5E and S5F).

To determine whether Arid1a−/+ GC B cells form MB cells more readily than their WT counterparts, we conducted mixed chimera experiments, transplanting Cd45.2; Arid1a+/− or Cd45.1/2; Arid1a+/+ bone marrow into lethally irradiated syngeneic recipients using several Arid1a+/−: Arid1a+/+ cell ratios (3:1, 1:1, and 1:3, Figure 6A). To control for variability in starting cell numbers, we normalized the cell counts to the respective naive B cell compartment (Figure 6B). Expectedly, Arid1a+/− GC B cells displayed a significant disadvantage compared to competing Arid1a+/+ GC B cells (Figure 6C). In contrast, we witnessed a significant competitive advantage of Arid1a+/− mice in forming MBs, regardless of the initial ratio of transferred cells (Figure 6D). The magnitude of this Arid1a+/− MB cell advantage was further accentuated when directly compared to their respective GC B cell populations (Figure 6E), suggesting that reduction in GC B cells may be due to preferential exit to the MB cell fate.

Figure 6. ARID1A loss boosts the generation of premature memory B cells predisposed to engage in germinal centers upon antigen recall.

Figure 6.

A. Experimental scheme and timeline for (C)–(E).

B. Representative FC plots and gating strategy of total splenocytes in mixed-bone marrow chimera animals (n=3 per group).

C. Relative GC B cell proportions compare to total naïve B cells as defined in (B). Horizontal lines represent median, dots represent replicates.

D. Relative MB cell proportions compare to total naïve B cells as defined in (B). Horizontal lines represent median, dots represent replicates.

E. Relative MB cell proportions compare to total GC B cells as defined in (B). Horizontal lines represent median, dots represent replicates.

F. Experimental scheme and timeline for (G) and (H).

G. Time-course FC analysis and quantification of cell type composition of antigen-specific MB cells. Bar plots showing mean, error bars represent SD, dots represent individual mice. t-test was used.

H. Day 49 FC analysis and quantification of cell type composition of antigen-specific MB cells. Bar plots of mean. Error bars represent SD and dots represent replicates. t-test was used.

I. FC analysis and quantification of GCB cells showing Arid1a+/− MB cells preferentially become GCB cells upon antigen recall (n=2). Non-immunized control mouse received Arid1a+/+ MB NP+ cells (generated by the initial NP-KLH immunization) but was not immunized with NP-OVA. Bar plots of mean. Error bars represent SD, dots represent replicates. t-test was used.

See also Figure S5.

MB cells can arise from GCs or extrafollicular populations54. To determine whether the observed MB cell advantage was a consequence of exiting GC B cells, we immunized mice with NP-KLH to track MB cells that have undergone affinity maturation for this antigen in the GC reaction. We examined NP-specific MB cell formation at d5, d11, d49 (Figure 6F). We confirmed GC B cells were less abundant, whereas the MB-containing B cell compartment was increased in Arid1a+/− animals (Figure S5G). We next measured NP-specific post-GC MB cell populations. We distinguished between IgG1+ vs. IgM+ MB cells, since previous reports suggested that IgM+ cells are less mature and could re-enter new GCs55–57. These analyses revealed a remarkable and dynamic distinction between genotypes. Arid1a+/− mice formed more NP+IgG1+ MBs at the earliest time point, but shifted to significantly more NP+IgM+ MBs at the mid-GC, and more importantly among long-term MB cells (Figure 6G).

MB cells are phenotypically and biologically heterogeneous. For example, MB cells with a CD80−PDL2− (double negative) immunophenotype are generally IgM+ and prone to re-enter GC reactions55. In contrast, CD80+PDL2+ (double positive) MB cells are generally IgG+ and only differentiate into PCs upon antigen recall. We observed that Arid1a+/− featured significantly increased abundance of CD80−PDL2− post-GC MBs and corresponding decrease in CD80+PDL2+ MBs (Figure 6H and S5H). In contrast we observed a decrease in bone marrow long-lived PCs (LLPC) at this late time point in Arid1a+/− mice (Figure S5I).

Our results so far suggest that Arid1a haploinsufficiency skews GC exit towards immature MB cells with high GC re-entry potential, to the detriment of LLPCs. To functionally validate this concept, we transferred Arid1a+/− or Arid1a+/+ antigen-specific MB (NP-KLH) into μMT recipient mice (which lack mature B cells)58. We co-transferred the recipients with OT-II memory T cells to enhance MB recall55,59. Recipient mice were immunized for recall using NP-OVA, and their entry into newly forming GCs was measured 3.5 days later. We observed a significant increase in the contribution of Arid1a+/− MB cells to new GCs as compared to their Arid1a+/+ counterparts (Figure 6I), confirming that ARID1A haploinsufficiency leads to abnormal expansion of MB capable of reinitiating GCs, hence readily undergoing sequential rounds of mutagenesis.

ARID1A is a haplo-insufficient tumor-suppressor in mouse GB cells

To determine whether ARID1A loss of function contributes to lymphomagenesis we crossed our Arid1a cKO mice with Bcl2 transgenic animals60, reflecting the common co-occurrence of ARID1A mutations and BCL2 translocations in FL and GCB-DLBCL28. We generated cohorts of Arid1a+/+ (Cg1Cre), Arid1a+/− (Arid1aflox/+;Cg1Cre), Bcl2;Arid1a+/+ (VavP-Bcl2), and Bcl2;Arid1a+/− (Arid1aflox/+; Cg1Cre;VavP-Bcl2) mice (n=30 mice per genotype), which were immunized with SRBC to initiate GCs and monitored for disease onset (Figure 7A). Four mice per cohort were sacrificed at five months to assess B cell phenotypes, which showed significantly increased abundance of GC B cells in Bcl2;Arid1a+/− mice vs. Bcl2;Arid1a+/+ (Figure 7B) and a more pronounced bias towards the CB population (Figure 7C), consistent with our observations in Arid1a+/− GCs (Figure S1C).

Figure 7. Arid1a deletion in mice decreases survival within lymphoma context and ARID1A deletion in follicular lymphoma patients is linked to transformation to aggressive disease.

Figure 7.

A. Experimental scheme and lymphomagenesis timeline for (B)–(F).

B. Representative FC plots and quantification of total B cells at the early lymphomagenesis time-point (n=4 per group). Bar plots of means. Error bars represent SD, dots represent individual mice. t-test was used.

C. Representative FC plots and quantification of GC B cells at the early lymphomagenesis time-point (n=4 per group). Bar plots of means. Error bars represent SD, dots represent individual mice. t-test was used.

D. Survival curves for lymphoma cohort mice. log-rank test was used.

E. Spleen size quantification at time of necropsy. Bar chart displaying mean spleen to body weight ratios, error bars representing SD, dots representing individual mice.

F. H&E of spleen sections from animals in (A) late time-point. Scale 100μm. Arrow indicates a mitotic figure.

G. Box and whisker plot showing the median, first and third quartiles, and the minimum and maximum of human ortholog GSVA scores of the mouse RNA signature comparing Arid1a+/− vs. Arid1a+/+ for Arid1a in patients from the NCI-DLBCL cohort. P-values were calculated by Wilcoxon rank-sum test.

H. UMAP dimensional reduction of CyTOF B cell data obtained from the combined analysis of 36 reactive lymph node (rLN) and 155 FL patient samples. Each dot in the plot represents a single cell, with cells colored according to their assigned cluster. The normal B cell populations in reactive lymph node (rLN) samples annotated based on the expression patterns of marker proteins as per 61. The contour lines on the plot represent the density of cells in the combined dataset.

I. UMAP as in (I) but with cells colored by patients (only patients with ARID1A mutations shown).

J. UMAP as in (I) but with cells colored by cluster (only memory-like B and D clusters are shown).

K. Number of cases with (ARID1A*) or without (WT) ARID1A mutations categorized. P-value calculated through Fisher’s Exact Test.

L. Kaplan-Meier curve showing risk of DLBCL transformation for patients in clusters B or D.

See also Figure S5.

Long-term follow-up of the remaining mice revealed significantly shorter survival for Bcl2;Arid1a+/− vs. Bcl2;Arid1a+/+ (p=0.0087) as well as vs. Arid1a+/+ and Arid1a+/−; Figure 7D). Bcl2;Arid1a+/− mice manifested greater spleen size (hence tumor burden) vs. Bcl2;Arid1a+/+ (Figure 7E). Histologically, Bcl2;Arid1a+/− lymphomas featured large, dysplastic immunoblasts with large, irregular nuclei and presence of mitotic figures (Figure 7F and S5J), similar traits as human transformed FLs/DLBCLs. These aberrant cells were frequently outside the follicular regions leading to marked disruption of the splenic architecture. In contrast, Bcl2;Arid1a+/+ mice displayed monotonous populations of smaller but still irregular lymphocytes, and better preservation of follicular architecture consistent with an earlier FL-like phenotype (Figure 7F and S5J). Collectively, these findings suggest that Arid1a functions as a haploinsufficient tumor suppressor that accelerates transformation of BCL2 induced FL-like disease to a transformed FL/DLBCL-like lymphoma.

ARID1A mutations are associated with the FL memory B cell subgroup of patients prone to transformation to DLBCL

To determine to what extent ARID1A deficient phenotypes in mice are reflected in humans, we examined whether the Arid1a+/− CC transcriptional signature was enriched in the RNA-seq profiles of GCB-DLBCL patients with either truncating (n=13) or missense (n=4) mutations vs. 121 patients with no mutations in any BAF subunit27. We noted that the Arid1a+/− CC signature was significantly enriched among ARID1A truncating (but not ARID1A missense) cases, vs. those without BAF mutations (Figure 7G).

To investigate whether Arid1a deficient phenotypes were also evident in primary human patients, we analyzed CyTOF profiles from a cohort of 155 newly diagnosed FL patients61. CyTOF profiles of these cases were shown to yield two major immunophenotypes: those resembling IgG+ GCB-like cells and those resembling IgM+ MB-like cells. We identified 13 ARID1A mutations in these patients (Figure 7H and I), nine of which were nonsense/frame-shift, and four missense mutations. Two of the missense mutations (L2238Q, K1772E) were located within the BAF250_C-domain, a region crucial for interactions with the BAF complex, and one (L1080R) within the ARID1A DNA-binding domain, implying potential deleterious impact. Analysis of these CyTOF profiles identified three clusters (B, D and Mem) of FLs with MB-like signatures (Figure 7J). Notably, we observed that ARID1A mutant FLs were significantly associated with the MB-like clusters (Figure 7K), most of which were IgM+61. Furthermore, these patients presented a significantly greater risk of transformation into DLBCL (Figure 7L). Hence our murine and human data converge to reveal that ARID1A deficiency favors formation of immature MB cells consistent with potential high-risk FL clonal precursor cells. We speculate that the heightened propensity of IgM+ MB cells to re-engage in proliferative bursts within new GCs may predispose these FLs to undergo DLBCL-like transformation.

ARID1A-mutant lymphoma cells show enhanced vulnerability to BAF complex inhibition

Considering that ARID1A loss-of-function significantly impairs the cBAF function, we hypothesized that survival of ARID1A mutant lymphoma cells might be dependent on remaining BAF complexes (cBAF or other). To test this, we subjected our Q474*/WT and WT/WT DLBCL cells to FHD-286, a highly potent and selective dual SMARCA4/2 allosteric ATPase inhibitor, currently in clinical trials for other tumors. Remarkably, Q474*/WT RIVA/R1 cells were eliminated by 10nM FHD-286 whereas WT/WT cells were largely unaffected after 6 days (p=0.003; Figure 8A). At 100nM there was still greater activity against ARID1A mutant cells, although WT cells were also affected (Figure 8B). In accordance with these results, Q474*/WT lymphoma cells manifested significantly lower IC50s as compared to WT/WT (p<0.0001; Figure S6A). We validated these results using the chemically unrelated and specific SMARCA4/2 degrader AU-1533062 (p<0.0001; Figure S6B). The impact of FHD-289 was primarily driven by apoptosis, which occurred at a significantly higher rate in Q474*/WT DLBCL cells (Figure 8C and S6C). Further justification for translation of BAF inhibitors for B cell lymphomas was afforded by examining the effect of ARID1A CRISPR knockout in 1145 cancer cell lines (DepMap). Notably, lymphoid neoplasms manifested the greatest dependency on ARID1A among all tumors (Figure 8D), with non-Hodgkin lymphomas being the most dependent subset (Figure 8E).

Figure 8. ARID1A deletion creates therapeutic vulnerability to BAF complex inhibition both in vitro and in vivo.

Figure 8.

A. Viability measurement over time for Q474*/WT and WT/WT cells treated with 10nM SMARCA4/2 inhibitor (FHD-286) including DMSO controls (black). Two independent experiments were performed, each with n=2. Line plot show viability measurement with lines connecting biological replicates. Points represent viability measurements. 2-way ANOVA applied.

B. Same as in (A) with 100nM FHD-286 treatment.

C. Apoptosis analysis using AnnexinV and 7-AAD. Bar plot of mean. Error bars represent SD, dots represent individual replicates. t-test was used.

D. DepMap Chronos score by tissue, ranked by ARID1A dependency.

E. Same as (A) but for cell lines with lymphoid tissue annotation.

F. In Vivo tumor growth inhibition means for xenograft animals (n=10 per genotype). Grey area represents 95% confidence interval.

G. Survival curves for all animals in the xenograft experiment.

H. Q474*/WT and WT/WT (either DMSO or FHD-286 treated) ATAC-seq PCA based on peaks with SD>0.5.

I. Heatmaps showing log2FC of differentially closing ATAC-seq loci upon FHD-286 treatment (WT-FHD-286 and HET-FHD-286 vs. WT DMSO).

J. Pseudo-median FPKM ATAC-seq of ATAC-seq WT DMSO, WT-FHD-286 and HET-FHD-286.

K. Regulatory potential showing top TFs with decreased motif accessibility upon FHD-286 treatment compared to DMSO colored by multivariate p.adj. Estimated coefficient shown as bar plots +/− 95% CI.

L. Genome browser ATAC-seq track showing Q474*/WT and WT/WT, DMSO or FHD-286 treated, we well as non-treated PU.1 CUT&RUN. IRF4 enhancer has been functionally verified previously 81.

M. Line plot showing mean viability measurement for WT and PU.1-KD cells treated with 100nM FHD-286. n=3. Error bars represent SD. 2-way ANOVA was used to calculate significance.

N. Same as in (M), except 10nM FHD-286 was used.

See also Figure S6 and Table S3.

Next, to determine the efficacy of FHD-286 in vivo, we generated xenografts from our Q474*/WT and WT/WT, isogenic cells using two separate clones. Mice were randomly assigned to FHD-286 or vehicle once tumors reached 40–70 mm3. FHD-286 was significantly more effective against Q474*/WT than WT xenografts, with 50% of animals experiencing tumor regression (Figure S6D-E and Figure 8F). In contrast there was no difference in tumor progression among vehicle treated WT/WT vs Q474*/WT lymphomas. This translated into a significant survival benefit for mice bearing Q474*/WT vs. WTWT isogenic lymphomas (p=0.0003; Figure 8G), confirming the more potent impact of SMARCA4/2 targeted therapy against ARID1A mutant lymphoma cells in vivo.

To better understand the nature of this vulnerability, we performed ATAC-seq in isogenic Q474*/WT and WT/WT DLBCL cells treated with either 100nM FHD-286 or vehicle for 24h. Hierarchical clustering and PCA distinctly separated samples first according to treatment effect and then by genotype (Figures 8H, S6F and Table S3). Notably, both Q474*/WT and WT/WT cells exhibited chromatin closure at matching locations following treatment, which was significantly more pronounced in Q474*/WT cells (Figure 8I and 8J). Regulatory potential analysis showed that PU.1 was the most affected TF, followed by NF-kB in both cases (Figure 8K and 8L), although the effect was more profound in Q474*/WT cells.

Finally, to determine whether impairment of PU.1 might at least partially explain the greater response of ARID1A mutant cells to BAF inhibitors, we generated WT/WT cell lines with stable integration of inducible shRNAs against PU.1 (PU.1-KD) or a non-targeting shRNA. Flow cytometry confirmed robust induction of the inducible vector and no leakiness (Figure S6G). Strikingly, PU.1-KD, but not non-targeting control, conferred significantly greater sensitivity to FHD-286 (Figure 8M, 8N and S6H), suggesting that loss of function of PU.1 contributes to vulnerability to BAF inhibitors. These findings suggest that ARID1A mutant lymphoma are highly sensitive to dual SMARCA4 and SMARCA2 ATPase inhibitors, warranting their clinical translation for BAF deficient lymphomas.

Discussion:

Our study reveals a pivotal role for ARID1A in the dynamics of chromatin regulation during the humoral immune response. We suggest a mechanism whereby loss of ARID1A function impairs PU.1 binding to chromatin, thus inhibiting the establishment of chromatin accessibility at adjacent NF-kB motifs. This reprograms GC B cells to adopt a memory-like transcriptional program, while attenuating PC formation normally facilitated by robust NF-kB activation. The abnormal pre-MB programming of ARID1A-deficient GC B cells likely diminishes their residency period within the GC reaction (hence the reduced CC abundance). This may reduce their opportunities for classs-witching and explain why ARID1A deficiency favors production of IgM+CD80-PDL2- MB cells with high GC re-entry potential, paving the way for additional rounds of somatic hypermutation and positioning these cells as putative clonal precursor cells.

TFs are known to cooperate on chromatin, highlighting their interdependence in gene regulation63,64. Of these, pioneer TFs uniquely bind both nucleosomal DNA and partially exposed DNA motifs, but still require nucleosome remodeling for chromatin opening65,66. Certain pioneer factors (OCT4, SOX2, AP1, PU.1) require BAF complex to mediate nearby nucleosome remodeling9,67–69. However, our understanding of how this pioneering function and chromatin opening influences subsequent binding of non-pioneering factors is limited. Our work provides insights into this process, demonstrating that NF-kB binding to specific target genes depends on PU.1 directed chromatin remodeling by the BAF complex. Furthermore, we show that proximity of NF-kB and PU.1 motifs is crucial for this function. Recent studies indicated that PU.1 can bind nucleosomal DNA even in the absence of chromatin remodeling70 but BAF complex is essential for spreading of chromatin accessibility, supporting our model of nucleosome-mediated TF co-dependency.

Genome-wide studies show that most potential DNA-binding sites for a given TF remain unbound, raising the question of how selective motif binding might occur. We propose that PU.1, by recruiting BAF complex, selectively unmasks NF-kB motifs that drive specific GC B cell exit programs, thus explaining context-specific NF-kB motif occupancy. Along these lines, Barozzi and colleagues71 showed that loci with tightly positioned nucleosomes flanking PU.1 motifs were enriched for NF-kB motifs in macrophages71. This observation supports our model that NF-kB binding to nucleosome-protected sites can occur only following PU.1-directed nucleosome remodeling in the GC B cell context.

PU.1 binds extensively to genes architecturally remodeled and activated in the GC reaction72. While an early study did not report defects in GC upon PU.1 knockout73, more recent conditional deletion of PU.1 in mature B cells revealed a decrease in GC B cells, a reduction in IgG1+ cells, and a trend towards reduction in post-GC PCs43. PU.1 deficient B cells were less responsive to CD40 and IL-4 signaling and showed downregulation of CD40 and other genes enriched in the ARID1A signature43. These observations notably mirror our findings, thereby supporting the idea that impaired PU.1 functionality is critical to the GC Arid1a haploinsufficient phenotype.

It is suggested that commitment to the MB cell pathway primarily occurs among intermediate antigen affinity GC B cells. These cells may experience BCR activation through interaction with follicular dendritic cells (FDCs), but may receive insufficient CD40 co-stimulatory signaling from follicular helper T (TFH) cells to engage in PC differentiation49. We put forth that a combination of diminished NF-kB-driven PC potential and enhanced MB cell programming contributes to curtailing the expansion of Arid1a deficient GCs, by facilitating early exit of GC B cells towards the MB cell fate.

MB cells have been proposed as likely clonal precursor cells for FLs74. IgM+ MB cells were described as potential normal equivalents to IgM+ lymphoma subtypes75, and quiescent clonal interfollicular memory-like cells were suggested to represent tumor reservoirs linked to FL therapy resistance76. BCL2 translocated t(14;18) positive B cells have been identified in normal donors77, were shown to derive from GCs, and often have an IgM+IgD+CD27+ MB-like phenotype78. In mice, IgM+ and IgG+ memory B cells follow unique paths, with the former exhibiting a lower somatic hypermutation load and the ability to enter new GCs, whereas the latter were more mutated, did not re-enter the GC reaction, and mainly differentiated into PCs 56,57. MB cells with a CD80-PDL2- phenotype were less mutated and more likely to re-enter new GC reactions, whereas CD80+PDL2+ MBs primarily formed PCs55. Finally, Sungalee and colleagues79 demonstrated that B cells overexpressing BCL2 predominantly displayed an IgM+ phenotype, and could enter new GCs in mice. Additionally, these mice exhibited incremental expansion and gradual increase in somatic hypermutation of GC and MB populations. Our research points to IgM+CD80-PDL2- MB cells being the specific type of clonal precursor cell giving rise to MB-like FLs at high risk of early transformation due to their inherent tendency to re-enter GCs and undergo proliferative bursting. Our discovery that these cells show synthetic lethality to BAF inhibitors provide an approach to specifically eliminate these clonal precursor cells, thus paving the way for early intervention trials in these high-risk FL patients.

STAR★Methods

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ari Melnick (amm2014@med.cornell.edu).

Materials availability

Cell lines generated in this study will be available upon reasonable request from the lead contact.

Data and code availability

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Mouse Models

The experimental procedures involving animals were executed in stringent accordance with the institutional guidelines delineated by Weill Cornell Medicine, as per the Guide for the Care and Use of Laboratory Animals 82, and standards established by the Association for Assessment and Accreditation of Laboratory Animal Care International. The Research Animal Resource Center, the Institutional Animal Care and Use Committee of Weill Cornell Medicine and Cornell Institutional Animal Care and Use Committee, having vetted all procedures, duly approved the entirety of the study involving mice under protocols #2011–0031 and #2017–0035. Experiments were uniformly performed on male and female mice that were age- and sex-matched, with the age bracket ranging from 8 to 16 weeks, barring any exceptions explicitly stated otherwise. All experimental groups incorporated both sexes, except for instances involving bone marrow transplantations, where donors were sex-matched, but the recipient mice were exclusively female. No evidence of sex-based influences or biases was observed. The following strains were obtained from The Jackson Laboratory: C57BL/6J (CD45.2, strain 000664), B6.SJL-PtprcaPepcb/BoyJ (CD45.1, SJL+/+, strain 002014), OT-II (strain 004194), Cg1Cre (strain 010611), muMT (strain 002288), NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557), Arid1a (strain 027717). Arid1a (strain 027717) were back-crossed to C57BL/6J genetic background through at least six generations before using for experiments. The VavP-Bcl2 83 model was developed by J. M. Adams (Walter and Eliza Hall Institute of Medical Research, Australia).

Cell Lines

The Raji cells were cultured with Roswell Park Memorial Institute (RPMI) medium supplemented with 20% Fetal Bovine Serum (FBS), 2 mmol/L L-glutamine, and 10 mmol/L HEPES. The RIVA (RI-1) cell line was propagated in Iscove’s Modified Dulbecco’s medium that was supplemented with 20% FBS and 2 mmol/L L-glutamine. In the case of the 293T cell line for virus production, it was cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS. Cell lines were grown under the presence of 1% penicillin G and streptomycin, maintained at 37°C within a humidified environment comprising 5% carbon dioxide. The RIVA cells were procured from Jose A. Martinez-Climent, (Universidad de Navarra, Pamplona, Spain). Routine examinations are performed within the laboratory to check for any potential mycoplasma contamination in the cell lines.

METHOD DETAILS

RNA Extraction and qPCR

Cells were harvested from culture and subsequently re-suspended in TRIzol (Invitrogen 15596018). Alternatively, cells were sorted directly into a more concentrated version of TRIzol reagent, TRIzol LS (Invitrogen 10296028), facilitating total RNA extraction. RNeasy Mini Kit (Qiagen #74104) was additionally harnessed to extract RNA from RIVA and Raji cell lines. Following extraction, the purified RNA was re-suspended in molecular-grade RNase-free water. RNA concentration was determined using the Qubit RNA High Sensitivity Kit (Thermo Fisher Q32855) and Nanodrop and RNA integrity was assessed using RNA 6000 Pico Kit (Agilent 5067–1513) on Agilent 2100 Bioanalyzer. Synthesis of cDNA was executed with consistent quantities of total RNA across all samples within each experiment, using the Verso cDNA Synthesis kit (Thermo Fisher AB1453B). Subsequent RT-qPCR was conducted on an equal volume of cDNA across all samples using a QuantStudio6 Flex Real-Time PCR System, coupled with Fast SYBR Green Master Mix (Thermo Fisher 4385614). The qPCR program had cycling stage; 95C for 30 sec, [95C for 3 sec, 60C for 30 sec] for 40 cycles. The qPCR signal for every gene was normalized with those of Gapdh by employing the delta-Ct method. The results were then shown as fold expression in comparison to wild type, inclusive of the standard deviation calculated from 3–4 biological replicates.

Virus Production and Infection

For the generation of NF-kB-RE luciferase reporter lentivirus particles, HEK293T cells were plated and transfected with a suspension containing the packaging plasmids psPax2 (Addgene 12260) and psMD2.G (Addgene 12259), alongside with the NF-kB reporter plasmid 46. This was performed at a ratio of 4:3:1 in serum-free media. The supernatant with viral particles was collected at 48h and 72h hours post-transfection and pooled, followed by filtration through a 0.45-μm filter, and subsequent concentration using PEG-it in accordance with the manufacturer’s protocol (LV825A-1 System Biosciences). The viral suspension was reconstituted with PBS and 25 μmol/L HEPES, and subsequently introduced to RIVA cell lines for infection. A selection was conducted 1 day post-transfection, involving the addition of puromycin for a minimum period of 7 days. For RNAi experiments, lentiviruses were generated in 293T cells by co-transfection of short hairpin RNA (shRNA) sequences. The shRNAs were designed using the SplashRNA algorithm 84 and cloned into LT3GEPIR (Adgene: 111177) Tet-ON miR-E (miR-30 variant)-based RNAi vector.

Antisense guide sequence used: ARID1A-7170: TATGTTTACAGTATCAGGTGTA, ARID1A-6964: TTACCATTAAAAACAGTTATGA, SPI1–1378: TTGAGAATAACTTTACTTGTTT, SPI11315: TCTGATTTACATACGGACTTGA, SPI1–1371: TAACTTTACTTGTTTTTTGGGA, SPI1–876: TAGGTCATCTTCTTGCGGTTGC, SPI1–1367: TTTACTTGTTTTTTGGGAGGAG. Raji cell line carrying NF-kB-RE cassette was infected with ARID1A knockdown constructs. Subsequently, knockdown was induced by the addition of doxycycline (1:1,000, 1mg/ml stock solution) for 24 hours and the GFP positive cells were sorted and transferred back to culture in media without doxycycline. In total four clones per cell line were kept based on their GFP positivity and frozen down to be used for further experiments.

CRISPR-Cas9 Gene Editing

In order to generate the ARID1A deletion model in lymphoma cell lines, we utilized Raji and RIVA (RI-1) lines. Exome sequencing revealed the presence of an ARID1A mutation, precisely Q474*, in the RIVA cell lines, which resulted in a premature stop codon on one allele. We confirmed this mutation via PCR amplicon sequencing on Illumina MiSeq of the mutated region, determining that Q474* was present at a rate of 50%, thereby affirming the heterozygous status of this mutation. We then employed targeted genome editing to revert the mutation to its wild type status. To accomplish this, the cells were electroporated with a ribonucleoprotein (RNP) complex, which contained the Alt-R recombinant S.p. HiFi Cas9 Nuclease (IDT 1081061), Alt-R CRISPR-Cas9 tracrRNA (IDT 1072534), and Alt-R CRISPR-Cas9 crRNA, the latter targeting the precise Q474* mutation region (GGACTTTACTGGTTGTAATA), as well as the WT DNA template (*A*C*AAGGCCCCAGCGGGTATGGTCAACAGGGCCAGACTCCATATTACAACCAGCAAAGT CCTCACCCTCAGCAGCAGCAGCCACCCTACTCCCAGCAA*C*C*A) (star sign indicates phosphorothioate nucleotides that were modified to ensure DNA stability). Electroporation was carried out in accordance with the manufacturer’s protocol using the SF Cell Line 96-well Nucleofector Kit (V4SC-2096). Subsequently, single cells were seeded into 96-well plates by single-cell fluorescence-activated cell sorting. Clones were screened and verified using both Sanger sequencing of PCR amplicons and Western Blot. Arid1a Q474* mutation was introduced in the Raji cell line by the same method, with the exception of using Alt-R CRISPR-Cas9 crRNA targeting WT allele (GGACTTTGCTGGTTGTAATA) and Q474* DNA template was used to introduce the mutation (ACAAGGCCCCAGCGGGTATGGTCAACAGGGCCAGACTCCATAcTACAAtCAGtAAAGTCCT CACCCTCAGCAGCAGCAGCCACCCTACTCCCAGCAACCA). Two silent mutations were introduced in the Q474* DNA template to ensure the CRISPR/Cas9 targeting was substantially reduced once the template is integrated into the locus (codon usage frequency was considered when designing silent mutations). For the introduction of a mutation into the PU.1 binding motif at the NF-kB luciferase reporter gene (NF-kB-RE Luc), the cells were electroporated with a RNP complex that was composed of the Alt-R recombinant S.p. Cas9 Nuclease V3 (IDT 1081059), Alt-R CRISPR-Cas9 tracrRNA (IDT 1073190), and two distinct Alt-R CRISPR-Cas9 crRNAs CD.Cas9.VPFX5778.AA (5’-UGGAAGCUCGACUUCAAGCUGUUUUAGAGCUAUGCU-3’) or CD.Cas9.VPFX5778.AC (5’-AUUAUAUACCCUCUAGUGUCGUUUUAGAGCUAUGCU-3’).

Immunoblot

Immunoblotting was conducted as follows: cells were lysed in RIPA buffer (20 mM HEPES KOH pH 7.5, 50 mM b-glycerophosphate, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 0.5 mM Na3VO4, 100 mM KCl, 10% glycerol, and 1% Triton X-100, supplemented with complete protease inhibitor cocktail; Roche #05056489001) and the lysates were subjected to resolution through SDS-PAGE, then transferred to a PVDF membrane overnight. The membrane was subsequently blocked with 5% milk (Biorad 1706404) for an hour and probed using primary antibodies. The membrane was then incubated with a corresponding peroxidase-conjugated secondary antibody (1:10,000 dilution Cell Signaling Technology, 7074 & 7076), and detected with chemiluminescence (WBKLS0500, Millipore & VWR #PI34095, Thermo Scientific) on a ChemiDoc Touch imaging system, ChemiDoc MP Imaging System (BioRad). Densitometry values were subsequently gathered using Fiji software and the Image Lab software v6.1.0 (Bio-Rad). Antibodies used: Arid1a:12354S (CST) 1:1,000 or Arid1a:HPA005456 (Sigma Aldrich) 1:1,000, Tubulin: T0198–25UL (Sigma) 1:5,000, NF-kB2: 37359S (CST) 1:1,000, PU.1 2266S (CST), 1:100.

Bulk ATAC-seq

ATAC-seq was prepared from FACS-sorted cell suspensions as per the Omni-ATAC protocol33. In brief, 50,000 freshly sorted live cells were rinsed in cold PBS and lysed in 50 μL of cold lysis buffer (comprising 10 mM Tris-HCl at pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.1% NP-40, 0.1% Tween-20, and 0.01% Digitonin) for 3 minutes on ice. This was followed by adding 1 mL wash buffer (comprising 10 mM Tris-HCl at pH 7.5, 10 mM NaCl, 3 mM MgCl2, and 0.1% Tween-20), and centrifugation to pellet nuclei. The nuclei were then resuspended in a transposition reaction mix that was prepared using the Illumina Tagment DNA TDE1 Enzyme and Buffer Kits (Illumina 20034197) and incubated at 37 ºC for 30 minutes on a thermomixer set at 1,000 rpm. Tagged DNA fragments were purified using the Clean & Concentrator-5 Kit (Zymo D4014) or AMPure XP beads (Beckman Coulter A63881) with a 2:1 bead-to-DNA ratio, and then subjected to PCR amplification to generate sequencing libraries. PCR amplicons were purified using AMPure XP beads at a 2:1 bead-to-DNA ratio. The size distribution and quality of the library were evaluated using the High Sensitivity DNA Kit (Agilent 5067–4626) and ran on the Agilent 2100 Bioanalyzer. The libraries were sequenced on Illumina HiSeq X and NovaSeq 6000 platforms using the HiSeq X Ten Reagent Kit (FC-501–2501) and PE50 SP Kit (Illumina 20028401), respectively.

CUT&RUN

For the Epicypher CUTANA Cut&Run protocol, 0.5M cell suspension was used for each sample. Post centrifugation, cells were resuspended in PBS, then fixed for a minute by adding 16% PFA directly into the tube to achieve a 0.1% PFA working concentration. This was followed by a strict 1-minute incubation at room temperature, after which the fixation was terminated with the addition of 1/20th glycine. After 5 minutes of chilling and subsequent centrifugation, the cells were permeabilized with Triton-X (0.1%) in Wash Buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM Spermidine (#S2501–1G), 1x Roche Complete Protease Inhibitor-mini (CPI-mini) EDTA-free (0505648900). The samples were then transferred to individual eppendorf tubes and chilled. After introducing Wash Buffer and centrifugation, the pellet was reconstituted in Wash Buffer and Concanavalin A beads (#NC 1526856) that were activated in Bead Activation Buffer (20 mM HEPES, pH 7.9 10 mM KCl, 1 mM CaCl2,1 mM MnCl2), and this cell-bead mixture was chilled for 10 minutes. The samples were then allocated into 8-well strip tubes and placed on a magnetic stand for supernatant removal. The beads were then incubated in the Antibody Buffer (Digitonin Buffer + 2 mM EDT) by adding the respective antibody in each tube (antibody added in 1:100 ratio), chilled, resuspended, and left to incubate overnight on a nutator. The next day, the supernatant was removed, and the beads were washed with Digitonin Buffer twice (Wash Buffer + 0.01% Digitonin 300410–250MG). Then, a pAG-MNase (SKU 15–1116) solution was introduced and samples were left at room temperature for 10 minutes. Post another supernatant removal, the beads were washed again twice with Digitonin Buffer, then treated with100mM CaCl2 in the same buffer. Following a 2-hour incubation at 4°C, a Stop Buffer (340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 50 μg/ml RNase A, 50 μg/ml Glycogen) was added and samples were left at 37°C for 10 minutes. After placing the 8-strip tubes on the magnetic stand, the supernatant was transferred to fresh tubes, and crosslinks were reversed by the addition of 0.09% SDS (V6551) and Proteinase K (Life Technologies 25530049). This mixture was then left to incubate overnight at 55°C in a PCR thermocycler and libraries were prepared following DNA purification. Antibodies used; ARID1A (1235S), IgG (ABIN101961), BRD9 (137245), PU.1 (2266S), H3.3 (91191), H3K27me3 (13027S).

ChIP-seq

ChIP-seq was carried out as previously described 85 with slight modifications. Changes to the protocol were following; (1) crosslinking was performed at 37C for 10min., (2) chromatin was sonicated for ~30 cycles of 30 sec. using a Diagenode Bioruptor, with 45 sec. breaks in between cycles, (3) protein A/G magnetic Dynabeads Magnetic beads (Thermo Fisher Scientific) were used for both pre-clearing and IP, (4) DNA was purified using on-column purification instead of chloroform/phenol extraction (Qiagen PCR Purification Kit). Immunoprecipitated DNA and input DNA were submitted to library preparation (NEBNext Ultra II DNA Library Prep Kit, Illumina). Antibodies used: PBRM1 (A301–591A), IgG (ABIN101961), SMARCA4 (A300–813A), PU.1 (2266S), H3K27ac (39133).

NEB Libraries

For the generation of libraries for next-generation sequencing (CUT&RUN, ChIP-seq, Amplicon-PCR) the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs #E7645L) was used. The fragmented DNA was subjected to end repair reaction followed by adaptor ligation. The NEBNext Adaptor for Illumina was diluted using 1:25 ratio with nuclease-free water. Following the adaptor ligation reaction, 1.1X of AMPure XP beads (Thermo Fischer Scientific #NC9933872) was added to the ligated samples to be purified. Finally, DNA was eluted in 0.1X TE. NEBNext Ultra II Q5 was used for PCR together with single (New England Biolabs #E6609S) or dual-indexes (New England Biolabs #E6440S). For CUT&RUN, PCR reaction was run according to the Epicypher CUT&RUN-specific PCR cycling parameters; 45 sec at 98C, [15 sec at 98C & 10 sec at 60C] 14x, 1 min at 72C. To purify PCR reaction products 1.1X AMPure XP beads was used.

Bone Marrow Transplantation

Bone marrow cells were collected from the femur and tibia of donor mice aged between 8 and 12 weeks, followed by treatment with a red blood cell lysis solution (Qiagen 158904). Lethally irradiated C57BL/6J host mice, who received two doses of 450 RAD via the Rad Source Technologies RS 2000 Biological Research X-ray Irradiator, were then injected with one million of these cells through the retro-orbital sinus. These transplanted mice were incorporated into experiments 8 to 14 weeks post-transplantation. Excluding the mice euthanized at predetermined intervals, all rodents participating in lymphomagenesis research were observed until they exhibited one or more conditions warranting euthanasia. These conditions included significant lethargy and body weight loss as well as discernible splenomegaly. This procedure aligns with the guidelines of our animal protocol approved by the Weill Cornell Medicine Institutional Animal Care and Use Committee (protocol #2011–0031).

Immunization

To induce germinal center (GC) formation in spleens, mice were immunized by intraperitoneal (i.p.) injection of 500 μL of 2% sheep red blood cells (SRBC) resuspended in sterile 1X DPBS from a solution of sheep blood in Alsever’s (Cocalico Biologicals 20–1334A), or by i.p. injection of 80 μg NP(30–32)-KLH (Biosearch Technologies N-5060) absorbed in alum adjuvant (ThermoFisher 77161) at a 1:1 ratio of alum:immunogen prior to injection.

Memory B Cell Recall

Memory B cells were sorted from mice with the indicated Arid1a genotypes as [Live, B220+, FASneg CD38+, IgDneg GL7neg, CD138neg, NP+ kappaNeg] either 49 days (replicate 1) or 161 days (replicate 2) after immunization with NP(30–32)-KLH as described above. On the same day, memory T cells were sorted from OT-II mice as [Live, B220neg CD3+, CD8neg CD4+, CD44hi CD62Lneg] 10 days after immunization by i.p. injection of 100 μg ovalbumin (albumin from chicken egg white, Sigma #A550, resuspended in sterile 1X DPBS and 0.2μm sterile-filtered) absorbed in alum adjuvant at a 1:2 ratio of alum:immunogen. We adoptively transferred 1,300 memory B cells (replicate 1) or 700–800 memory B cells (replicate 2) plus 50,000 memory T cells per μMT mouse recipient. μMT mice lack mature B cells, allowing specific detection of those derived from transferred cells. OT-II memory T cells were used to boost memory B recall 55. On the next day (day 50 replicate 1, day 162 replicate 2), μMT recipient mice were immunized by i.p. injection of 80 μg NP(19)-OVA (Biosearch Technologies N-5051) absorbed in alum adjuvant (ThermoFisher 77161) at a 1:1 ratio of alum:immunogen. One μMT mouse from replicate 2 had received the same number of memory B and memory T cells but was not immunized with NP-OVA as control. Recall was assessed 3.5 days after (day 54 replicate 1, day 166 replicate 2), to exclude confounding factors such as differences in GC expansion that might occur later.

H&E Staining and Immunohistochemistry

Mouse organs were fixed in 10% neutral buffered formalin (Sigma) for 24–48h and transferred to 70% ethanol. Tissues were then embedded in paraffin, processed and stained at the Laboratory of Comparative Pathology (WCM/MSKCC). Briefly, 5 μm sections were deparaffinized and stained with hematoxylin and eosin (H&E) or processed for immunohistochemistry by heat antigen-retrieval in citrate buffer at pH 6.4, followed by treatment with 3% hydrogen peroxide in methanol to block endogenous peroxidase (HRP) activity. Indirect immunohistochemistry was then performed using biotinylated peanut agglutinin (PNA, Vector Laboratories B1075) or anti-species-specific biotinylated secondary antibodies, followed by avidin-horseradish peroxidase and development with DAB substrate (Vector Laboratories). Sections were counterstained with hematoxylin. The following primary antibodies were used: anti-B220 (BD 550286) and anti-Ki67 (Cell Signaling Technology 12202).

Flow Cytometry

Spleens were mashed, splenocytes were filtered through a 40 μm cell strainer and mononuclear cells enriched by density gradient centrifugation using Ficoll-Paque Premium (Cytiva 17–5442-02). Resulting single cell suspensions were resuspended in PBE (PBS with EDTA) with 0.5 μg/mL rat anti-mouse CD16/CD32 (clone 2.4G2, BD) and incubated for ≥5 min on ice to block Fc receptors. Without wash, cells were stained for 20 min on ice, in a mix of fluorochrome-conjugated anti-mouse antibodies diluted either in PBE, or in a 50:50 mixture of Brilliant Stain Buffer (BD 566349) and PBS with 0.5% BSA but without EDTA when the mix contained ≥2 BV- or BUV-conjugated antibodies, to avoid staining artifacts due to interaction between these fluorescent dyes. All cells were then washed twice before analysis. For PD-L2 staining, cells were then blocked a second time in PBE containing 10% rat plus 10% mouse serum for at least 10 minutes (to prevent anti-IgG1 to cross react with PD-L2) prior to staining for at least 25 minutes with anti-PD-L2 antibody, diluted in the same mixture of PBE plus 10% rat and 10% mouse serum. Cells were then washed twice before analysis. DAPI (ThermoFisher D1306) was added just prior to acquisition at final 0.5 μg/mL for the exclusion of dead cells. Data was acquired on BD Symphony A3 and analyzed using FlowJo software package (TreeStar). Antibody dilutions used: B220-BV786; clone RA3–6B2, BD 563894 (dilution 1:300), CD138-BUV737 clone 281–2, BD 564430 (dilution 1:500), CD38-APC; clone 90, eBioscience 17–0381-81 (dilution 1:500), CD38-BUV395; clone 90, BD 740245 (dilution 1:500), CD38-BUV563; clone 90, BD 741271 (dilution 1:400), CD80-BV421; clone 16–10A1, BioLegend 104725 (dilution 1:300), CD86-BV605; clone GL-1, BioLegend 105037 (dilution 1:200), CXCR4-biotin; clone 2B11, BD 551968 (dilution 1:200), FAS-BUV805; clone Jo2, BD 741968 (dilution 1:100), FAS-PE-Cy7; clone Jo2, BD 557653 (dilution 1:500), GL7-FITC; clone GL7, BD 553666 (dilution 1:500), GL7-PerCPCy5.5; clone GL7, BioLegend 144610 (dilution 1:500), IgD-BV510; clone 11–26c.2a, BD 563110 (dilution 1:500), IgG1-BV650; clone RMG1–1, BioLegend 406629 (dilution 1:500), IgM-BUV661; clone II/41, BD 750660 (dilution 1:300), IgM-BUV805; clone II/41, BD 749307 (dilution 1:500), IgM-FITC; clone II/41, BD 553437 (dilution 1:300), kappa-APC-Cy7; clone RMK-45, BioLegend 409503 (dilution 1:200), PD-L2-BUV395; clone TY25, BD 565102 (dilution 1:75), CD3-APC, clone 17A2, BioLegend 100235 (dilution 1:500), CD4-APC-Cy7, clone GK1.5, BioLegend 100414 (dilution 1:500), CD8-Pe-Cy7, clone 53–6.7, BioLegend 100722 (dilution 1:400), CD44-BUV395, clone IM7, BD Biosciences 740215, (dilution 1:200), CD62L-BV605, clone MEL-14, BioLegend 104437 (dilution 1:400), kappa-APC-Cy7; clone RMK-45, BioLegend 409503 (dilution 1:200). Secondary: SA-APC-Cy7; BioLegend 405208 (dilution 1:100). Other: NP-PE; N-5070–1 (diluted to 5μg/mL).

Xenograft Mouse Experiment

Forty-eight NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient mice were subcutaneously implanted with 1×10^7 cells and Corning Matrigel in a total volume of 200uL. Four cell lines were used for implantation: two Q474*/WT and two WT/WT clones. Animals were monitored twice per week for tumor growth using digital calipers. Once tumor burden reached 32mm^3 as calculated by the formula (LxW2)/2 animals were assigned into one of two groups FHD286 or control vehicle for all four cell lines n=5 per group. Treatment by oral gavage was performed twice per day, FHD286 was formulated at a stock concentration of 04.mg/mL and animals were dosed at 1.5mg/kg in a 90% saline/captisol and 10% DMSO vehicle for thirty days. Body condition, body weight, and tumor burden were assessed three time per week while animals were on study. Wet food was provided in cage at ten percent body weight loss and were euthanized if weight loss exceeded more than twenty percent as compared to day one of dosing. Animals were also euthanized if tumor burden became detrimental to animal health impairing movement or causing moribund behavior. At time of sacrifice animals were euthanized using CO2 asphyxiation, the tumor was excised and weighed. It is often observed in experimental therapeutic studies that female mice are less robust than males, given their lower baseline body weights and high metabolic needs. We observed a similar phenomenon here whereby the females lost weight and hence did not experience the same degree of benefit as the male mice. There was no difference in outcome based on which clones were implanted.

Luciferase Assay

The Dual-Luciferase Reporter 1000 Assay System (Promega #E1980) was used to determine Luciferase activity in the RIVA and Raji cell lines. Specifically, 125,000 cells from each sample were gathered and spun down at 300xg for 5 minutes. Each of these cell pellets was then reconstituted in 200ul of media that contained either DMSO (Sigma Aldrich D8418–500ML) or PMA (Santa cruz Biotechnology SC-3576A) and ionomycin (Santa cruz Biotechnology I0634–1MG), serving to stimulate the cells. The resuspended samples were then transferred to a 96-well U-bottom plate and incubated at 37°C for an hour. Following this incubation period, the plate was centrifuged again at 300xg for 5 minutes. The supernatant was carefully discarded, and the cell pellets were rinsed with 200ul of 1X DPBS. This centrifugation process was then repeated, after which the cells were lysed using 50ul of PLB lysis Buffer (Promega E194A). The plate was then subjected to shaking for 15 minutes at RT. Once the incubation was complete, a 20ul aliquot from each sample was transferred to a white flat-bottom 96-well plate. This plate was then loaded into the Biotek plate reader to determine the background luminescence without the addition of any substrate. To quantify the Firefly Luciferase signal, 50ul of reconstituted Luciferase Assay Reagent II (Substrate E151C reconstituted in Buffer E195C) was added to each well, and the luminescence indicative of the firefly luciferase signal was measured. Following this, an additional 50ul of the Stop & Glo Reagent (50X Stop & Glo Substrate #E640B in Stop & Glo Buffer #E641B to achieve 1X final concentration for the substrate) was added to each well to quench the firefly luminescence and simultaneously activate the Renilla luciferase, whose signal was then measured.

MNase-seq

5.5×106 cells were resuspended in 1mL of buffer 1 (0.3M Sucrose, 15mM Tris pH 7.5, 60mM KCl, 15mM NaCl, 5mM MgCl2, 2mM EDTA, 0.5mM DTT, 1x PIC, 0.2mM spermine, 1mM spermidine) with 0.02% NP-40 and incubated on ice for 5 minutes. Samples were then spun down at 300xg for 5 min at 4C. The pellets were resuspended in 1mL of buffer 2 (0.3M Sucrose, 15mM Tris pH 7.5, 60mM KCl, 15mM NaCl, 5mM MgCl2, 0.5mM DTT, 1x PIC, 0.2mM spermine, 1mM spermidine) and spun down at 300xg for 5 min at 4C. Nuclei integrity was checked before continuing with protocol and only samples that had nuclei recovery >85% were processed. Pellets were resuspended in 400ul MNase buffer (0.3M Sucrose, 50mM Tris ph 7.5, 4mM MgCl2, 1mM CaCl2, 1x PIC) and 3–5U of MNase S7 micrococcal nuclease (Roche) was added. Samples were incubated at 37C for 30 minutes. EDTA (5mM) was added to stop the reaction. SDS (1% final concentration) and Proteinase K (200ug/mL) were added and samples were incubated for 1 hour at 55C with shaking. DNA was purified using the Qiagen PCR Purification Kit and digestion efficiency was assessed using an Agilent Bioanalyzer. The mononucleasomal fraction was purified using Ampure XP beads (1.1X) and libraries were prepared using NEBNext Ultra II Library Preparation Kit, using 8 PCR cycles and 100ng of starting DNA.

Bulk RNA-seq

Library preparation, sequencing and post-processing of raw data was performed at the Genomics Core at Weill Cornell Medicine. Library preparation using the Illumina TruSeq Stranded mRNA Library prep kit (Illumina, 20020594) and sequenced with PE50 paired end-sequencing, performed on an Illumina HiSeq4000 sequencer.

Multiome Single Cell RNA and ATAC Sequencing

Single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) libraries were prepared employing the 10X Genomics Single Cell Multiome assay kit (10X Genomics; 1000230, 1000283, 1000494, 1000215, 1000212) following the manufacturer’s guidelines. Briefly, GC cells from splenocytes were sorted using antibody cocktails described above (Flow Cytometry), rinsed with 0.04% BSA PBS, and 100,000 cells underwent the manufacturer’s nuclei preparation procedure and a combination of regulat and low-input protocol was used. Then, about 20,000 nuclei were placed into a 10x Chromium X instrument. The remainder of the library preparation steps were conducted in accordance with the manufacturer’s protocol. Libraries were evaluated using an Agilent Bioanalyzer, quantified utilizing a KAPA Library Quantification Kit, and sequenced on an Illumina Novaseq platform.

Targeted Sequencing

Targeted sequencing of FL patients was performed as described previously 61. Mainly, we used the TruSeq Custom Amplicon assay (TSCA; mean coverage: 767; range: 128–2,039; SD: 180) to identify variants within the protein coding regions of 59 genes commonly mutated in human B-cell lymphomas that includes ARID1A. TSCA variants were validated with the Fluidigm Access Array system which achieved a 97% validation rate. Discrepancies between TSCA and Fluidigm results were further validated by Sanger sequencing.

Targeted Sequencing Data Analysis

Reads were mapped with BWA (v0.7.5a). SNVs and indels were predicted with Mutascope (v1.02). SAMtools (v0.1.19) was used to create pileup files and dbSNP (v137) for SNP annotation. All variants with an allele frequency of ≥5% at loci covered at least 50-fold were retained.

Bulk ATAC-seq Analysis

Raw reads were checked by FastQC 86. Sequence adapters were trimmed by Trim Galore! and the resulting reads were aligned to the mm10 or hg38 genome reference with BWA 87,88. Duplicate reads were marked by Picard 89. After the alignment, mitochondrial reads, duplicate reads, reads in blacklisted regions, secondary alignments and multimapping reads, reads with insert size greater than 2kb or wrong orientation of the pairs, or orphan reads were filtered. Peaks were called using MACS2 narrow peak calling with shift of −75 bp and extension of 150 bp 90. ATAC-seq quality was performed by checking the fragment length distribution, FRIP scores, TSS enrichment and high quality autosomal reads using Picard, ataqv and MultiQC 91,92. Consensus peaks were called by taking the overlap of regions covered in at least 2 of the samples. Reads within peaks were quantified using featureCounts 93. Variance stabilizing transform (vst) was used for normalizing the data for visualizations and unsupervised clustering 94. The differential peak accessibility was called by negative binomial model using DESeq2 using multivariate models and filtering for an absolute log2-fold-change value of log2(1.5) (0.58) and FDR adjusted p-value of 0.01 94. The peaks were annotated and collapsed to genes by taking the maximally changing peak with respect to p-value within 5kb of each transcription start site and assigning that peak to each gene by their promoter, or alternatively putative proximal enhancers in their regulatory regions defined by GREAT 95. The genes were ranked by the log2-fold-change value or the Wald statistic and fed into GSEA using MSigDB database and the curated gene signatures from the RNA-seq experiments as well as literature. An adjusted p-value of 0.05 was used to filter the resulting gene sets 96,97. Regulatory potential of transcription factors was calculated by comparing all the mammalian motifs in JASPAR within the sequences of accessible peaks 32,98. The log2 fold-changes of peak accessibility were modeled against the presence of such motifs in a multivariate manner while correcting for GC content, i.e. log2FC ~ β0 + β1∗ 𝑥1 + β2∗𝑥2+ … + β𝑁∗GC, where xi denotes a Boolean variable for the presence of a TF motif in a peak as a binary variable and GC is the GC-content of the peak. The effect sizes and p-values for each term are taken after multivariate linear modeling using ordinary least squares regression with robust standard errors. As an orthogonal method, TF binding sites, binding scores, and differential binding between conditions were assessed by TOBIAS by footprinting analysis 42. Pseduomedians and 95% confidence intervals were determined using the wilcox.test() function from the R framework (v3.4.3). Read density heatmaps were generated from normalized bigwigs using the deepTools suite (v3.5.1). See also Tables S1-3.

Bulk RNA-seq Analysis

Reads were trimmed with TrimGalore!, and mapped to mm10 or hg38 genome reference using STAR and Gencode gene annotations 87,99,100. Counts were assigned into transcripts and genes using featureCounts 93. Differential gene expression was calculated using a negative binomial model with DESeq2, using univariate models for RIVA/RI-1, and multivariate models correcting for cell type and genotype in the mouse models. Genes were considered differentially expressed with an absolute fold change greater than log2(1.5) and adjusted p-value of less than 0.01 94. The correlation between RNA-seq and ATAC-seq was performed by taking all the ATAC-seq peaks within 10kb of the transcription start site of every gene and binning the genes into differentially opening or closing and non-differential categories, and plotting the log2-fold-change of expression differences.

CUT&RUN Analysis

Sequencing QC and adapter trimming were performed by FastQC and Trimmomatic 86,101. Trimmed sequences were aligned to the hg38 genome for RIVA samples by Bowtie2, and filtered for mapping reads with proper pairs and duplicate marked using samtools 102,103. All read fragments were utilized during the analysis of histone marks and BAF complex proteins. For all the other transcription factors the sequences were filtered to fragments with insert sizes less than 120 base pairs. Resulting alignments were converted into track files by RPKM normalization using deepTools 104. Peaks were called using seacr with stringent method and 1% threshold 105. Consensus peaks between different replicates and conditions were merged by collapsing all peaks by any amount of overlap, then filtering to merged peaks that have at least 3 replicates as called peaks. Reads within the peaks were quantified using featureCounts and normalized using variance-stabilizing transform in DESeq2 for visualization purposes, such as heatmaps, unsupervised clustering, t-SNE and PCA93,94,106. Differential peak binding was calculated with a negative binomial model and TMM normalization using DESeq2.

ChIP-seq Analysis

Raw read QC and adapter trimming were performed by FastQC and TrimGalore!, and reads were aligned to the hg38 genome reference using BWA 86–88. Duplicate reads were marked by Picard 89. After the alignment, duplicate reads, reads in blacklisted regions, secondary alignments and multimapping reads, reads with insert size greater than 2kb or wrong orientation of the pairs, or orphan reads were filtered. Peaks were called for each IP against the control samples using MACS2 90,107.

MNase-seq Analysis

MNase-seq data was processed and filtered in a similar manner to ChIPseq, utilizing FastQC, Trim Galore!, BWA alignment, Picard and samtools filtering 86–89,103. After alignment and filtering, DANPOS3 was used for nucleosome occupancy prediction, nucleosome fuzziness, and differential nucleosome binding 35,108. Smoothed predicted nucleosome occupancy tracks were quantile normalized for each condition. To create the meta-plots either the TSSs of canonical isoforms of genes, or the summits of ATACseq peaks were taken. Occupancy scores were calculated at 10bp bins, and the median of those values were taken summarizing across the flanking regions of TSSs or peak summits. The meta profiles were normalized by dividing the profile of each replicate by its median and multiplying by the median of all the conditions in a 2kb window.

Chromatin Segmentation and Clustering Analysis

The workflow for segmenting chromatin into regions with distinct epigenomic marks comprised four main steps: 1- Defining regions via peak clustering, 2- Quantifying these regions, 3- Clustering these regions, and 4- Matching the regions with read-out values from other epigenomic marks. In the peak clustering step, peak calls from every mark relevant for genome segmentation (e.g., ATACseq, H3K27ac, H3K27me3) were extended to at least 500bp. A graph, which represented the combined data from all replicates of all marks, was created. Each peak was treated as a node, and nodes were connected with a vertex only if the corresponding peaks overlapped by 50% in both directions. As a result, two peaks situated roughly in the same location and having similar sizes shared an edge. However, a broad peak encompassing a much smaller peak did not have an edge with the smaller one if the latter was less than 50% the size of the broad peak. Connected components within the graph were identified, and the members of each component were collapsed into a single region by extending their start and end coordinates to their furthest extents within the component. Unconnected peak nodes retained their original coordinates. The start and end coordinates of this refined peak set served as boundaries, segmenting the chromatin into disjoint regions. This new set of regions was cross-referenced with the initial peak calls across different marks and replicates. Any region with fewer than two separate overlaps was discarded. Following this, immediately adjacent regions showing similar peak presence or absence patterns across various replicates, as defined by a Hamming distance of less than 2, were combined to generate the final set of segments. Subsequently, featureCounts was employed to quantify reads within each segment. The counts were then normalized to log(FPKM + 1). For each segment, the median log FPKM value was calculated for all replicates of a specific mark and genotype. For each mark, the log2 fold-change for Het vs WT and KD vs WT was calculated based on the difference between the log FPKM values. This yielded baseline WT logFPKM values and Het Vs WT log2 fold-change values for ATACseq, H3K27ac, and H3K27me3 marks, and an additional KD vs WT value for ATACseq. These seven metrics were used to cluster all regions into 16 groups using k-means clustering. Marks that were not considered during peak definition or clustering were used as read-outs. The quantification and normalization of these marks were done similarly, using featureCounts for quantification, log FPKM for normalization, and the calculation of Het vs WT log2 fold-change. Additionally, differential gene expression data from RNAseq experiments were used as an independent read-out, by associating each region with the gene having the closest transcription start site (TSS). To summarize, these clusters were represented as either the median signal across all regions within a cluster or as violin plots. External annotations from Human GCB enhancers and predicted transcription factor binding sites (TFBS) from TOBIAS were also included in the summary plot 32. Original code has been deposited at: https://github.com/melnick-lab/Barisic_et_al_CancerCell_2024/. See also Table S2.

Multiome Analysis

Multiome fastq files were aligned and processed with CellRanger Arc version 2.0.0 (10x Genomics). CellRanger outputs were then further processed individually with Signac version 1.5.0 109. Peaks were called with MACS2 using default settings 110. Samples were combined together, and a combined peak set was generated from all samples. Peaks larger than 10kb and less than 20 bases were filtered from this combined peak set. Harmony version 0.1.0 was used on PCA based on RNA and LSI based on ATAC to correct batch effect between experiments 111. Signac FindMultiModalNeighbors was used on these Harmony corrected values to generate multimodal nearest neighbors upon which the UMAP is based. Cell type labels were assigned based on RNA expression using the Seurat TransferLabel function and reference datasets 47. Gene signature module scores for expression were calculated using the AddModuleScore function, with a control value of 5. Slingshot version 2.8.0 was used to generate Pseudotime based on the first and second Harmony corrected PCA of expression, with the starting anchor being Centroblasts. Density and difference in density of cells for WT and ARID1A HET along this pseudotime was caluclated, with significance being tested using wilcoxon rank sum of this pseudotime. ChromVAR scores for the JASPAR2020 core, vertebrates motif list were calculated with Signac’s AddMotif and RunChromVAR functions on the filtered, combined peak set. The indicated gene signature or ChromVAR accessibility of the indicated motif were plotted against pseudotime, which was broken into 10 deciles. Expression of these gene signatures or ChromVAR accessibility for each decile was then tested for significance between WT and ARID1A HET using wilcoxon rank sum. The difference in splines were plotted and colored according to decile significance. Pre-plasma cells were defined as cycling BCL6-low non-pre-memory cells. Code for multiome processing can be found at https://github.com/crchin/multiome_process.

Quantification and Statistical Analyses

Statistical parameters including the exact value of n and precision measures (mean or median ± SD) and statistical significance are reported in the Figures and Figure Legends. Data is judged to be statistically significant when p<0.05 or padj<0.05 by the indicated test. We analyzed survival data using Kaplan-Meier curves and assessed differences between groups through the log-rank test. Statistical analysis was performed using R environment (version 4.1.0) and Prism GraphPad (version 8.0).

Statistical analysis of Sequencing data is described under Method Details section and in Figure Legends.

Supplementary Material

MMC4

Table S3. Detailed FHD286 ATAC peak information related to Figure 8.

MMC3
MMC1

Table S2. Detailed peak information related to Figure 3.

MMC2

Table S1. Detailed peak information and key gene signature names related to Figure 2.

Key resources table

REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-rabbit Cell Signaling Technology Cat# 7074S; RRID:AB_330924
Anti-mouse Cell Signaling Technology Cat# 7076S; RRID:AB_2099233
Arid1a Sigma Aldrich Cat# HPA005456; RRID:AB_1078205
Arid1a Cell Signaling Technology Cat# 12354S; RRID:AB_2637010
Tubulin Sigma Aldrich Cat# T0198–25UL; RRID:AB_477556
SMARCA4 Thermo Fisher Scientific Cat# 07–478; RRID:AB_310650
PU.1 Cell Signaling Technology Cat# 2266S; RRID:AB_10692379
NF-kB2 Cell Signaling Technology Cat# 37359S; RRID:AB_2799114
NF-kB1 Cell Signaling Technology Cat# 13586S; RRID:AB_2665516
p65 Cell Signaling Technology Cat# 8242T; RRID:AB_10859369
PBRM1 Bethyl Cat# A301–591A-T; RRID:AB_1078808
IgG Antibodies-online Cat# ABIN101961; RRID:AB_10775589
Brd9 Abcam Cat# 137245
Brg1 Bethyl Cat# A300–813A-M; RRID:AB_2191850
Biotinylated peanut agglutinin Vector Laboratories Cat# B1075; RRID:AB_2313597
anti-B220 BD Cat# 550286; RRID:AB_393581
anti-Ki67 Cell Signaling Technology Cat# 12202; RRID:AB_2620142
H3.3 Active Motif Cat # 91191; RRID:AB_2793796
H3K27me3 Cell Signaling Technology Cat# 9733S; RRID:AB_2616029
H3K27ac Active Motif Cat# 39133; RRID:AB_2561016
B220-BV786 (clone RA3–6B2) BD Cat# 563894; RRID:
AB_2738472
CD138-BUV737 (clone 281–2) BD Cat# 564430; RRID: AB_2738805
CD38-APC (clone 90) eBioscience Cat# 17–0381-81; RRID:AB_469381
CD38-BUV395 (clone 90) BD Cat# 740245; RRID:AB_2739992
CD38-BUV563 (clone 90) BD Cat# 741271; RRID:AB_2870812
CD80-BV421 (clone 16–10A) BioLegend Cat# 104725; RRID:AB_10900989
CD86-BV605 (clone GL-1) BioLegend Cat# 105037; RRID:AB_11204429
CXCR4-biotin (clone 2B11) BD Cat# 551968; RRID:AB_394307
FAS-BUV805 (clone Jo2) BD Cat# 741968; RRID:AB_2871273
FAS-PE-Cy7 (clone Jo2) BD Cat# 557653; RRID:AB_396768
GL7-FITC (clone GL7) BD Cat# 553666; RRID:AB_394981
GL7-PerCPCy5.5 (clone GL7) BioLegend Cat# 144610; RRID:AB_2562979
IgD-BV510 (clone 11–26c.2a) BD Cat# 563110; RRID:AB_2737003
IgG1-BV650 (clone RMG1–1) BioLegend Cat# 406629; RRID:AB_2716013
IgM-BUV661 (clone II/41) BD Cat# 750660; RRID:AB_2874787
IgM-BUV805 (clone II/41) BD Cat# 749307; RRID:AB_2873681
IgM-FITC (clone II/41) BD Cat# 553437; RRID:AB_394857
kappa-APC-Cy7 (clone RMK-45) BioLegend Cat# 409503; RRID:AB_2563578
PD-L2-BUV395 (clone TY25) BD Cat# 565102; RRID:AB_2739068
CD3-APC (clone 17A2) BioLegend Cat# 100235; RRID:AB_2561455
CD4-APC-Cy7 (clone GK1.5) BioLegend Cat# 100414; RRID:AB_312699
CD8-Pe-Cy7, clone 53–6.7 BioLegend Cat# 100722; RRID:AB_312761
CD44-BUV395, clone IM7 BD Cat# 740215; RRID:AB_2739963
CD62L-BV605, clone MEL-14, BioLegend Cat# 104437; RRID:AB_11125577
kappa-APC-Cy7; clone RMK-45 BioLegend Cat# 409503; RRID:AB_2563578
SA-APC-Cy7 BioLegend Cat# 405208
NP-PE LGC Biosearch Technologies Cat# N-5070–1
Bacterial and virus strains
Biological samples
Chemicals, peptides, and recombinant proteins
TRIZOL Invitrogen Cat# 15596018
TRIZOL LS Invitrogen Cat# 10296028
PMA Santa cruz Biotechnology Cat# SC-3576A
Ionomycin Sigma Aldrich Cat# I0634–1MG
16% PFA Life Technologies Cat# 28906
Spermidine Sigma Aldrich Cat# S2501–1G
Digitonin VWR Cat# 80055–226
Doxycycline Thermo Fisher Scientific Cat# BP26531
Puromycin Thermo Fisher Scientific Cat# NC9138068
RNase-Free DNase Set Qiagen Cat# 79254
Tn5 transposase Illumina Cat#20034198
BioMag Plus Concanavalin A Beads Thermo Fisher Scientific Cat# NC1526856
CUTANA pAG-MNase Epicypher Cat# 15–1116
Proteinase K Life Technologies Cat# 25530049
Dynabead Protein A Thermo Fischer Scientific Cat# 10002D
Dynabead Protein G Thermo Fischer Scientific Cat# 10004D
UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) Life Technologies Cat # 15593031
Critical commercial assays
Illumina Tagment DNA TDE1 Enzyme and Buffer Kits Illumina Cat# 20034197
Clean & Concentrator-5 Kit Zymo Cat# D4014
High Sensitivity DNA Kit Agilent Cat# 5067–4626
Dual-Luciferase Reporter 1000 Assay System Promega Cat# E1980
NEBNext Ultra II DNA Library Prep Kit for Illumina New England Biolabs Cat# E7645L
SF Cell Line 96-well Nucleofector Kit Lonza Bioscience Cat# V4SC-2096
DNeasy Blood and Tissue Kit Qiagen Cat# 69504
llumina TruSeq Stranded mRNA Library prep kit Illumina Cat# 20020594
HiSeq X Ten Reagent Kit Illumina Cat# FC-501–2501
PE50 SP Kit Illumina Cat# 20028401
RNeasy Mini Kit Qiagen Cat# 74104
Qubit RNA High Sensitivity Kit Thermo Fisher Cat# Q32855
RNA 6000 Pico Kit Agilent Cat# 5067–1513
Verso cDNA Synthesis kit Thermo Fisher Cat# AB1453B
10X Genomics Single Cell Multiome assay kit 10X Genomics Cat# 1000230; Cat# 1000283; Cat# 1000494; Cat# 1000215; Cat# 1000212
QIAquick PCR purification Kit Qiagen Cat# 28106
Deposited data
Genomic data This paper GSE237990
Original code This paper https://github.com/melnick-lab/Barisic_et_al_CancerCell_2024/
Original code – Multiome process This paper https://github.com/crchin/multiome_process
msigdb Castanza et al. 2023 https://www.gsea-msigdb.org/gsea/msigdbGSE89897
Prememory Gene Signature Laidlaw et al. 2017
CyTOF Profiles Wang et al. 2022 #EGAS00001004085, #EGAS00001005257
Experimental models: Cell lines
RIVA (RI-1) Jose A. Martinez-Climent Laboratory, Universidad de Navarra, Pamplona, Spain RRID:CVCL_1885
Raji ATCC RRID:CVCL_0511
HEK293T ATCC RRID:CVCL_0063
Experimental models: Organisms/strains
C57BL/6J (CD45.2) International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:000664
B6.SJL-PtprcaPepcb/BoyJ (CD45.1, SJL+/+) International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:002014
Cd19Cre International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:006785
Cg1Cre International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:010611
Arid1aCre International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:027717
VavP-Bcl2 (48) Walter and Eliza Hall Institute of Medical Research, Australia N/A
OT-II International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:004194
muMT International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:002288
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ International Mouse Resource Center IMSR, JAX RRID:IMSR_JAX:005557
Oligonucleotides
Alt-R CRISPR-Cas9 tracrRNA IDT Cat# 1073190; Cat# 1072534
Alt-R CRISPR-Cas9 crRNA CD.Cas9.VPFX5778.AA (5’-UGGAAGCUCGACUUCAAGCUGUUUUAGAGCUAUGCU-3’) This paper N/A
Alt-R CRISPR-Cas9 crRNA CD.Cas9.VPFX5778.AC (5’-AUUAUAUACCCUCUAGUGUCGUUUUAGAGCUAUGCU-3’) This paper N/A
shRNA ARID1A-7170: TATGTTTACAGTATCAGGTGTA This paper N/A
shRNA ARID1A-6964: TTACCATTAAAAACAGTTATGA This paper N/A
shRNA SPI1–1378: TTGAGAATAACTTTACTTGTTT This paper N/A
shRNA SPI1–1315: TCTGATTTACATACGGACTTGA This paper N/A
shRNA SPI1–1371: TAACTTTACTTGTTTTTTGGGA This paper N/A
shRNA SPI1–876: TAGGTCATCTTCTTGCGGTTGC This paper N/A
shRNA SPI1–1367: TTTACTTGTTTTTTGGGAGGAG This paper N/A
Recombinant DNA
psPax2 Trono Lab Packaging and Envelope Plasmids Addgene 12260; RRID:Addgene_12260
psMD2.G Trono Lab Packaging and Envelope Plasmids Addgene 12259; RRID:Addgene_12269
Software and algorithms
FlowJo, version 10.5.3 Becton Dickinson https://www.flowjo.com
Prism GraphPad, version 8.0 Dotmatics https://www.graphpad.com/
Other
Nitrocellulose Transfer Membranes+A115:C132 VWR Cat# 27376–991
Milk Biorad Cat# 1706404
Single indexes New England Biolabs Cat# E6609S
Dual indexes New England Biolabs Cat# E6440S
S.p. HiFi Cas9 Nuclease IDT Cat# 1081061
S.p. Cas9 Nuclease V3 IDT Cat# 1081059
Complete protease inhibitor cocktail Roche Cat# 5056489001
AMPure XP beads Beckman Coulter Cat# A63881
Fast SYBR Green Master Mix Life Technologies Cat# 4385614
Red blood cell lysis solution Qiagen Cat# 158904
PEG-it System Biosciences Cat# LV825A-1
Nuclease-free water Invitrogen Cat# AM9937
SuperSignal West Femto Maximum Chemiluminescent Substrate VWR Cat# PI34095
Sheep blood in Alsever’s Cocalico Biologicals Cat# 20–1334A
NP(30–32)-KLH Biosearch Technologies Cat# N-5060
NP(19)-OVA Biosearch Technologies Cat# N-5051
Alum adjuvant ThermoFisher Cat# 77161
Pierce ChIP-grade Protein A/G Magnetic Beads Life Technologies Cat # 26162
FuGENE HD Transfection Reagent Promega Cat # E2311
DAB substrate Vector Laboratories Cat# SK-4100
Ovalbumin Sigma Cat# A550

Highlights:

  • ARID1A enables stepwise and cooperative chromatin binding for PU.1 and NF-kB factors

  • Multiome analysis shows ARID1A loss drives cell-fate toward memory B cell program

  • ARID1A loss links memory-like FLs to higher DLBCL transformation risk in patients

  • ARID1A-mutant lymphoma cells show enhanced vulnerability to BAF complex inhibition

Acknowledgements:

We thank S. Manalis, C. Kadoch, O. Elemento, A. Krebs and D. Schuebeler for valuable feedback. We thank the Melnick Lab for their help, H. Shen, G. Fayzikhodjaeva and R. Hughes for support with mouse colonies. We thank the Green and Landau Labs for feedback and support, Foghorn Therapeutics for providing FHD-286, and the Epigenomics, Genomics, and Flow Cytometry cores (WCM); Rishi Puri and the PATh PDX/CDX & Surgical Facility (Cornell University); the Molecular Cytology core (MSKCC); and the Center of Comparative Medicine and Pathology (WCM/MSKCC). This work was supported by: D.B.: Swiss National Science Foundation Fellowship, National Cancer Center Postdoctoral Fellowship; K99/R00 NIH NCI Path To Independence Award 5K99CA246080-02. C.R.C.: 5 F31 CA254302-02. C.M.: ASH Award ASHI 204241-01, LRF Fellowship LSRMP-817214. M.X.: LSS (5483-19). B.P.: Deutsche Forschungsgemeinschaft PE3140/1-1. A.P.W.: Terry Fox Research Institute (grant 1061) and the BC Cancer Foundation. D.W.S.: Michael Smith Foundation for Health Research Health Professional Investigator award (18646). M.R.G. and C.E.M.: R01 CA266279. M.R.G.: Leukemia and Lymphoma Society Scholar Award. C.E.M. thanks the Scientific Computing Unit (SCU) at WCM, the WorldQuant and GI Research Foundation, the NIH (R01MH117406, P01CA214274, R01CA249054), and LLS (MCL7001-18, LLS 9238-16, 7029-23). A.M.: R35 CA220499, LLS SCOR 7021-20, IFLI collaborative research award.

Declaration of Interest:

A.M. has research funding from Janssen, Epizyme and Daiichi Sankyo. A.M. consulted for Exo Therapeutics, Treeline Biosciences, Astra Zeneca, Epizyme. C.S. consulted for Seattle Genetics, AbbVie, and Bayer and received research funding from Bristol Myers Squibb, Epizyme and Trillium Therapeutics Inc. D.W.S. received honoraria from Abbvie, AstraZeneca, Incyte and Janssen and research funding from Janssen and Roche. C.E.M. is a cofounder and board member for Biotia and Onegevity Health as well as advisor or grantee for Abbvie, ArcBio, Daiichi Sankyo, DNA Genotek, Tempus Labs, and Whole Biome. M.R.G. reports research funding from Sanofi, Kite/Gilead, Abbvie and Allogene; consulting for Abbvie, Allogene and Bristol Myers Squibb; honoraria from BMS, Daiichi Sankyo and DAVA Oncology; and stock ownership of KDAc Therapeutics. CM consulted for Thorne HealthTech.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References:

  • 1.Delmas V, Stokes DG, and Perry RP (1993). A mammalian DNA-binding protein that contains a chromodomain and an SNF2/SWI2-like helicase domain. Proceedings of the National Academy of Sciences 90, 2414–2418. 10.1073/pnas.90.6.2414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Shen X, Mizuguchi G, Hamiche A, and Wu C. (2000). A chromatin remodelling complex involved in transcription and DNA processing. Nature 406, 541–544. 10.1038/35020123. [DOI] [PubMed] [Google Scholar]
  • 3.Tsukiyama T, Daniel C, Tamkun J, and Wu C. (1995). ISWI, a member of the SWl2/SNF2 ATPase family, encodes the 140 kDa subunit of the nucleosome remodeling factor. Cell 83, 1021–1026. 10.1016/0092-8674(95)90217-1. [DOI] [PubMed] [Google Scholar]
  • 4.Tamkun JW, Deuring R, Scott MP, Kissinger M, Pattatucci AM, Kaufman TC, and Kennison JA (1992). brahma: A regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2SWI2. Cell 68, 561–572. 10.1016/0092-8674(92)90191-E. [DOI] [PubMed] [Google Scholar]
  • 5.Whitehouse I, Flaus A, Cairns BR, White MF, Workman JL, and Owen-Hughes T. (1999). Nucleosome mobilization catalysed by the yeast SWI/SNF complex. Nature 400, 784–787. 10.1038/23506. [DOI] [PubMed] [Google Scholar]
  • 6.Kassabov SR, Zhang B, Persinger J, and Bartholomew B. (2003). SWI/SNF Unwraps, Slides, and Rewraps the Nucleosome. Mol Cell 11, 391–403. 10.1016/S1097-2765(03)00039-X. [DOI] [PubMed] [Google Scholar]
  • 7.Kwon H, Imbalzano AN, Khavari PA, Kingston RE, and Green MR (1994). Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 370, 477–481. 10.1038/370477a0. [DOI] [PubMed] [Google Scholar]
  • 8.Centore RC, Sandoval GJ, Soares LMM, Kadoch C, and Chan HM (2020). Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. Trends in Genetics 36, 936–950. 10.1016/j.tig.2020.07.011. [DOI] [PubMed] [Google Scholar]
  • 9.Barisic D, Stadler MB, Iurlaro M, and Schübeler D. (2019). Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. Nature 569, 136–140. 10.1038/s41586-019-1115-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, and Crabtree GR (1996). Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 10, 2117–2130. 10.1101/gad.10.17.2117. [DOI] [PubMed] [Google Scholar]
  • 11.Ho L, Ronan JL, Wu J, Staahl BT, Chen L, Kuo A, Lessard J, Nesvizhskii AI, Ranish J, and Crabtree GR (2009). An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proceedings of the National Academy of Sciences 106, 5181–5186. 10.1073/pnas.0812889106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mashtalir N, D’Avino AR, Michel BC, Luo J, Pan J, Otto JE, Zullow HJ, McKenzie ZM, Kubiak RL, St. Pierre, R., et al. (2018). Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes. Cell 175, 1272–1288.e20. 10.1016/j.cell.2018.09.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mashtalir N, Suzuki H, Farrell DP, Sankar A, Luo J, Filipovski M, D’Avino AR, St. Pierre R, Valencia AM, Onikubo T., et al. (2020). A Structural Model of the Endogenous Human BAF Complex Informs Disease Mechanisms. Cell 183, 802–817.e24. 10.1016/j.cell.2020.09.051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.He S, Wu Z, Tian Y, Yu Z, Yu J, Wang X, Li J, Liu B, and Xu Y. (2020). Structure of nucleosome-bound human BAF complex. Science (1979) 367, 875–881. 10.1126/science.aaz9761. [DOI] [PubMed] [Google Scholar]
  • 15.Raab JR, Resnick S, and Magnuson T. (2015). Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes. PLoS Genet 11, 1–26. 10.1371/journal.pgen.1005748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, and Crabtree GR (2013). Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45, 592–601. 10.1038/ng.2628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wang Z, Chen K, Jia Y, Chuang J-C, Sun X, Lin Y-H, Celen C, Li L, Huang F, Liu X, et al. (2020). Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes. Nat Cancer 1, 909–922. 10.1038/s43018-020-00109-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, and Roberts CWM (2016). ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet 49, 296–302. 10.1038/ng.3744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Blümli S, Wiechens N, Wu M-Y, Singh V, Gierlinski M, Schweikert G, Gilbert N, Naughton C, Sundaramoorthy R, Varghese J, et al. (2021). Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcription. Cell Rep 37, 109943. 10.1016/j.celrep.2021.109943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sun X, Wang SC, Wei Y, Luo X, Jia Y, Li L, Gopal P, Zhu M, Nassour I, Chuang J-C, et al. (2017). Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. Cancer Cell 32, 574–589.e6. 10.1016/j.ccell.2017.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, et al. (2018). Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173, 371–385.e18. 10.1016/j.cell.2018.02.060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, et al. (2020). Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation 130, 2712–2726. 10.1172/JCI134402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Xu S, and Tang C. (2021). The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? Front Oncol 11. 10.3389/fonc.2021.745187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al. (2011). Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303. 10.1038/nature10351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, et al. (2015). Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences 112. 10.1073/pnas.1501199112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Okosun J, Bödör C, Wang J, Araf S, Yang C-Y, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, et al. (2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46, 176–181. 10.1038/ng.2856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al. (2018). Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine 378, 1396–1407. 10.1056/NEJMoa1801445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, et al. (2020). A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37, 551–568.e14. 10.1016/j.ccell.2020.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. (2018). Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24, 679–690. 10.1038/s41591-018-0016-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Mlynarczyk C, Fontán L, and Melnick A. (2019). Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunol Rev 288, 214–239. 10.1111/imr.12755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Mesin L, Ersching J, and Victora GD (2016). Germinal Center B Cell Dynamics. Immunity 45, 471–482. 10.1016/j.immuni.2016.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Doane AS, Chu C-S, Di Giammartino DC, Rivas MA, Hellmuth JC, Jiang Y, Yusufova N, Alonso A, Roeder RG, Apostolou E, et al. (2021). OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. Nat Immunol 22, 1327–1340. 10.1038/s41590-021-01025-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, Satpathy AT, Rubin AJ, Montine KS, Wu B, et al. (2017). An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods 14, 959–962. 10.1038/nmeth.4396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Pan J, McKenzie ZM, D’Avino AR, Mashtalir N, Lareau CA, St. Pierre R., Wang L, Shilatifard A, and Kadoch C. (2019). The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity–independent genomic targeting. Nat Genet 51, 618–626. 10.1038/s41588-019-0363-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chen K, Xi Y, Pan X, Li Z, Kaestner K, Tyler J, Dent S, He X, and Li W. (2013). DANPOS: Dynamic analysis of nucleosome position and occupancy by sequencing. Genome Res 23, 341–351. 10.1101/gr.142067.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho Y-J, Koellhoffer EC, Pomeroy SL, Orkin SH, and Roberts CWM (2010). Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation. Cancer Cell 18, 316–328. 10.1016/j.ccr.2010.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kadoch C, Williams RT, Calarco JP, Miller EL, Weber CM, Braun SMG, Pulice JL, Chory EJ, and Crabtree GR (2017). Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet 49, 213–222. 10.1038/ng.3734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Tagami H, Ray-Gallet D, Almouzni G, and Nakatani Y. (2004). Histone H3.1 and H3.3 Complexes Mediate Nucleosome Assembly Pathways Dependent or Independent of DNA Synthesis. Cell 116, 51–61. 10.1016/S0092-8674(03)01064-X. [DOI] [PubMed] [Google Scholar]
  • 39.Ahmad K, and Henikoff S. (2002). The Histone Variant H3.3 Marks Active Chromatin by Replication-Independent Nucleosome Assembly. Mol Cell 9, 1191–1200. 10.1016/S1097-2765(02)00542-7. [DOI] [PubMed] [Google Scholar]
  • 40.Dion MF, Kaplan T, Kim M, Buratowski S, Friedman N, and Rando OJ (2007). Dynamics of Replication-Independent Histone Turnover in Budding Yeast. Science (1979) 315, 1405–1408. 10.1126/science.1134053. [DOI] [PubMed] [Google Scholar]
  • 41.Ise W, Fujii K, Shiroguchi K, Ito A, Kometani K, Takeda K, Kawakami E, Yamashita K, Suzuki K, Okada T, et al. (2018). T Follicular Helper Cell-Germinal Center B Cell Interaction Strength Regulates Entry into Plasma Cell or Recycling Germinal Center Cell Fate. Immunity 48, 702–715.e4. 10.1016/j.immuni.2018.03.027. [DOI] [PubMed] [Google Scholar]
  • 42.Bentsen M, Goymann P, Schultheis H, Klee K, Petrova A, Wiegandt R, Fust A, Preussner J, Kuenne C, Braun T, et al. (2020). ATAC-seq footprinting unravels kinetics of transcription factor binding during zygotic genome activation. Nat Commun 11, 4267. 10.1038/s41467-020-18035-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Willis SN, Tellier J, Liao Y, Trezise S, Light A, O’Donnell K, Garrett-Sinha LA, Shi W, Tarlinton DM, and Nutt SL (2017). Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB. Nat Commun 8, 1426. 10.1038/s41467-017-01605-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Batista CR, Li SKH, Xu LS, Solomon LA, and DeKoter RP (2017). PU.1 Regulates Ig Light Chain Transcription and Rearrangement in Pre-B Cells during B Cell Development. The Journal of Immunology 198, 1565–1574. 10.4049/jimmunol.1601709. [DOI] [PubMed] [Google Scholar]
  • 45.DeKoter RP, Lee H-J, and Singh H. (2002). PU.1 Regulates Expression of the Interleukin-7 Receptor in Lymphoid Progenitors. Immunity 16, 297–309. 10.1016/S1074-7613(02)00269-8. [DOI] [PubMed] [Google Scholar]
  • 46.Xia M, David L, Teater M, Gutierrez J, Wang X, Meydan C, Lytle A, Slack GW, Scott DW, Morin RD, et al. (2022). BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer Discov, OF1–OF20. 10.1158/2159-8290.CD-21-1566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Rivas MA, Durmaz C, Kloetgen A, Chin CR, Chen Z, Bhinder B, Koren A, Viny AD, Scharer CD, Boss JM, et al. (2021). Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. Front Immunol 12. 10.3389/fimmu.2021.688493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, Purdom E, and Dudoit S. (2018). Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 19, 477. 10.1186/s12864-018-4772-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Laidlaw BJ, and Cyster JG (2021). Transcriptional regulation of memory B cell differentiation. Nat Rev Immunol 21, 209–220. 10.1038/s41577-020-00446-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Laidlaw BJ, Duan L, Xu Y, Vazquez SE, and Cyster JG (2020). The transcription factor Hhex cooperates with the corepressor Tle3 to promote memory B cell development. Nat Immunol 21, 1082–1093. 10.1038/s41590-020-0713-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Bhattacharya D, Cheah MT, Franco CB, Hosen N, Pin CL, Sha WC, and Weissman IL (2007). Transcriptional Profiling of Antigen-Dependent Murine B Cell Differentiation and Memory Formation. The Journal of Immunology 179, 6808–6819. 10.4049/jimmunol.179.10.6808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kuo TC, Shaffer AL, Haddad J, Choi YS, Staudt LM, and Calame K. (2007). Repression of BCL-6 is required for the formation of human memory B cells in vitro. Journal of Experimental Medicine 204, 819–830. 10.1084/jem.20062104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Laidlaw BJ, Schmidt TH, Green JA, Allen CDC, Okada T, and Cyster JG (2017). The Eph-related tyrosine kinase ligand Ephrin-B1 marks germinal center and memory precursor B cells. Journal of Experimental Medicine 214, 639–649. 10.1084/jem.20161461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Elsner RA, and Shlomchik MJ (2020). Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity. Immunity 53, 1136–1150. 10.1016/j.immuni.2020.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zuccarino-Catania GV, Sadanand S, Weisel FJ, Tomayko MM, Meng H, Kleinstein SH, Good-Jacobson KL, and Shlomchik MJ (2014). CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat Immunol 15, 631–637. 10.1038/ni.2914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Pape KA, Taylor JJ, Maul RW, Gearhart PJ, and Jenkins MK (2011). Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune Response. Science (1979) 331, 1203–1207. 10.1126/science.1201730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Dogan I, Bertocci B, Vilmont V, Delbos F, Mégret J, Storck S, Reynaud C-A, and Weill J-C (2009). Multiple layers of B cell memory with different effector functions. Nat Immunol 10, 1292–1299. 10.1038/ni.1814. [DOI] [PubMed] [Google Scholar]
  • 58.Kitamura D, Roes J, Kühn R, and Rajewsky K. (1991). A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature 350, 423–426. 10.1038/350423a0. [DOI] [PubMed] [Google Scholar]
  • 59.Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR, et al. (2020). TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell 182, 297–316.e27. 10.1016/j.cell.2020.05.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Egle A, Harris AW, Bath ML, O’Reilly L, and Cory S. (2004). VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276–2283. 10.1182/blood-2003-07-2469. [DOI] [PubMed] [Google Scholar]
  • 61.Wang X, Nissen M, Gracias D, Kusakabe M, Simkin G, Jiang A, Duns G, Sarkozy C, Hilton L, Chavez EA, et al. (2022). Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat Commun 13, 6772. 10.1038/s41467-022-34408-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, Carson SE, Chang Y, Wang X, Zhang Y, et al. (2022). Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature 601, 434–439. 10.1038/s41586-021-04246-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Zaret KS, and Carroll JS (2011). Pioneer transcription factors: establishing competence for gene expression. Genes Dev 25, 2227–2241. 10.1101/gad.176826.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Iwafuchi-Doi M, and Zaret KS (2014). Pioneer transcription factors in cell reprogramming. Genes Dev 28, 2679–2692. 10.1101/gad.253443.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Michael AK, Grand RS, Isbel L, Cavadini S, Kozicka Z, Kempf G, Bunker RD, Schenk AD, Graff-Meyer A, Pathare GR, et al. (2020). Mechanisms of OCT4-SOX2 motif readout on nucleosomes. Science (1979) 368, 1460–1465. 10.1126/science.abb0074. [DOI] [PubMed] [Google Scholar]
  • 66.Soufi A, Garcia MF, Jaroszewicz A, Osman N, Pellegrini M, and Zaret KS (2015). Pioneer Transcription Factors Target Partial DNA Motifs on Nucleosomes to Initiate Reprogramming. Cell 161, 555–568. 10.1016/j.cell.2015.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.King HW, and Klose RJ (2017). The pioneer factor OCT4 requires the chromatin remodeller BRG1 to support gene regulatory element function in mouse embryonic stem cells. Elife 6. 10.7554/eLife.22631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wolf BK, Zhao Y, McCray A, Hawk WH, Deary LT, Sugiarto NW, LaCroix IS, Gerber SA, Cheng C, and Wang X. (2023). Cooperation of chromatin remodeling SWI/SNF complex and pioneer factor AP-1 shapes 3D enhancer landscapes. Nat Struct Mol Biol 30, 10–21. 10.1038/s41594-022-00880-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Chambers C, Cermakova K, Chan YS, Kurtz K, Wohlan K, Lewis AH, Wang C, Pham A, Dejmek M, Sala M, et al. (2023). SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer Res 83, 983–996. 10.1158/0008-5472.CAN-22-2129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Frederick MA, Williamson KE, Fernandez Garcia M, Ferretti MB, McCarthy RL, Donahue G, Luzete Monteiro E, Takenaka N, Reynaga J, Kadoch C, et al. (2023). A pioneer factor locally opens compacted chromatin to enable targeted ATP-dependent nucleosome remodeling. Nat Struct Mol Biol 30, 31–37. 10.1038/s41594-022-00886-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Barozzi I, Simonatto M, Bonifacio S, Yang L, Rohs R, Ghisletti S, and Natoli G. (2014). Coregulation of Transcription Factor Binding and Nucleosome Occupancy through DNA Features of Mammalian Enhancers. Mol Cell 54, 844–857. 10.1016/j.molcel.2014.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Bunting KL, Soong TD, Singh R, Jiang Y, Béguelin W, Poloway DW, Swed BL, Hatzi K, Reisacher W, Teater M, et al. (2016). Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity 45, 497–512. 10.1016/j.immuni.2016.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Polli M, Dakic A, Light A, Wu L, Tarlinton DM, and Nutt SL (2005). The development of functional B lymphocytes in conditional PU.1 knock-out mice. Blood 106, 2083–2090. 10.1182/blood-2005-01-0283. [DOI] [PubMed] [Google Scholar]
  • 74.Milpied P, Gandhi AK, Cartron G, Pasqualucci L, Tarte K, Nadel B, and Roulland S. (2021). Follicular lymphoma dynamics. In, pp. 43–103. 10.1016/bs.ai.2021.05.002. [DOI] [PubMed] [Google Scholar]
  • 75.Klein U, Küppers R, and Rajewsky K. (1997). Evidence for a Large Compartment of IgM-Expressing Memory B Cells in Humans. Blood 89, 1288–1298. 10.1182/blood.V89.4.1288. [DOI] [PubMed] [Google Scholar]
  • 76.Dogan A, Du M-Q, Aiello A, Diss TC, Ye H-T, Pan L-X, and Isaacson PG (1998). Follicular Lymphomas Contain a Clonally Linked But Phenotypically Distinct Neoplastic B-Cell Population in the Interfollicular Zone. Blood 91, 4708–4714. 10.1182/blood.V91.12.4708. [DOI] [PubMed] [Google Scholar]
  • 77.Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen G, Schuuring E, and Kluin P. (1995). Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85, 2528–2536. 10.1182/blood.V85.9.2528.bloodjournal8592528. [DOI] [PubMed] [Google Scholar]
  • 78.Roulland S, Navarro J-M, Grenot P, Milili M, Agopian J, Montpellier B, Gauduchon P, Lebailly P, Schiff C, and Nadel B. (2006). Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. Journal of Experimental Medicine 203, 2425–2431. 10.1084/jem.20061292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Sungalee S, Mamessier E, Morgado E, Grégoire E, Brohawn PZ, Morehouse CA, Jouve N, Monvoisin C, Menard C, Debroas G, et al. (2014). Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. Journal of Clinical Investigation 124, 5337–5351. 10.1172/JCI72415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, et al. (2021). Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107, 690–701. 10.3324/haematol.2020.274258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Wood CD, Carvell T, Gunnell A, Ojeniyi OO, Osborne C, and West MJ (2018). Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells. J Virol 92. 10.1128/JVI.00716-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Guide for the Care and Use of Laboratory Animals (2011). (National Academies Press; ) 10.17226/12910. [DOI] [PubMed] [Google Scholar]
  • 83.Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, and Adams JM (1999). Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proceedings of the National Academy of Sciences 96, 14943–14948. 10.1073/pnas.96.26.14943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Pelossof R, Fairchild L, Huang C-H, Widmer C, Sreedharan VT, Sinha N, Lai D-Y, Guan Y, Premsrirut PK, Tschaharganeh DF, et al. (2017). Prediction of potent shRNAs with a sequential classification algorithm. Nat Biotechnol 35, 350–353. 10.1038/nbt.3807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, and Schübeler D. (2007). Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39, 457–466. 10.1038/ng1990. [DOI] [PubMed] [Google Scholar]
  • 86.Andrews S. (2010). FastQC: A quality control tool for high throughput sequence data. Http://Www.Bioinformatics.Babraham.Ac.Uk/Projects/Fastqc/.citeulike-article-id:11583827. [Google Scholar]
  • 87.Krueger F. (2016). Trim Galore. Babraham Bioinformatics http://www.bioinformatics.babraham.ac.uk/projects/trimgalore/. [Google Scholar]
  • 88.Li H, and Durbin R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 10.1093/bioinformatics/btp324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Broad Institute (2016). Picard tools https://broadinstitute.github.io/picard/. [Google Scholar]
  • 90.Gaspar JM (2018). Improved peak-calling with MACS2. bioRxiv. [Google Scholar]
  • 91.Orchard P, Kyono Y, Hensley J, Kitzman JO, and Parker SCJ (2020). Quantification, Dynamic Visualization, and Validation of Bias in ATAC-Seq Data with ataqv. Cell Syst. 10.1016/j.cels.2020.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Ewels P, Magnusson M, Lundin S, and Käller M. (2016). MultiQC: Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 10.1093/bioinformatics/btw354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Liao Y, Smyth GK, and Shi W. (2014). FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 10.1093/bioinformatics/btt656. [DOI] [PubMed] [Google Scholar]
  • 94.Love MI, Huber W, Anders S, Lönnstedt I, Speed T, Robinson M, Smyth G, McCarthy D, Chen Y, Smyth G, et al. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, and Bejerano G. (2010). GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 10.1038/nbt.1630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, and Mesirov JP (2011). Molecular signatures database (MSigDB) 3.0. Bioinformatics. 10.1093/bioinformatics/btr260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Berhanu Lemma R, Turchi L, Blanc-Mathieu R, Lucas J, Boddie P, Khan A, Perez NM, et al. (2022). JASPAR 2022: The 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 10.1093/nar/gkab1113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, et al. (2012). GENCODE: The reference human genome annotation for the ENCODE project. Genome Res. 10.1101/gr.135350.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Bolger AM, Lohse M, and Usadel B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics. 10.1093/bioinformatics/btu170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Langmead B, and Salzberg S. (2013). Bowtie2. Nat Methods. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, and Durbin R. (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics. 10.1093/bioinformatics/btp352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dündar F, and Manke T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 10.1093/NAR/GKW257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Meers MP, Tenenbaum D, and Henikoff S. (2019). Peak calling by Sparse Enrichment Analysis for CUT&RUN chromatin profiling. Epigenetics Chromatin. 10.1186/s13072-019-0287-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Van Der Maaten L, and Hinton G. (2008). Visualizing data using t-SNE. Journal of Machine Learning Research. [Google Scholar]
  • 107.Liu T. (2014). Use model-based analysis of chIP-seq (MACS) to analyze short reads generated by sequencing protein–DNA interactions in embryonic stem cells. Methods in Molecular Biology. 10.1007/978-1-4939-0512-6_4. [DOI] [PubMed] [Google Scholar]
  • 108.Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X, et al. (2015). Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nat Genet. 10.1038/ng.3385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Stuart T, Srivastava A, Madad S, Lareau CA, and Satija R. (2021). Single-cell chromatin state analysis with Signac. Nat Methods 18, 1333–1341. 10.1038/s41592-021-01282-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. (2008). Model-based Analysis of ChIP-Seq (MACS). Genome Biol 9, R137. 10.1186/gb-2008-9-9-r137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P, and Raychaudhuri S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16, 1289–1296. 10.1038/s41592-019-0619-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

MMC4

Table S3. Detailed FHD286 ATAC peak information related to Figure 8.

MMC3
MMC1

Table S2. Detailed peak information related to Figure 3.

MMC2

Table S1. Detailed peak information and key gene signature names related to Figure 2.

Data Availability Statement

RESOURCES